

A

06/23/99  
jc520 U.S. PTO

NEW UNITED STATES UTILITY PATENT APPLICATION  
under 37 C.F.R. 1.53(b)

Atty. Docket No. 04435/79243

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10: The undersigned hereby certifies that this United States Patent Application and all papers noted herein as being attached, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 today, **June 23, 1999**, and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

By: Andrea MacVarish  
Andrea MacVarish

Express Mail Label No.: EL199779661US

jc530 U.S. PTO  
09/338855  
06/23/99

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Enclosed herewith is a new patent application and the following papers:

Inventors (or application identifier): **Joseph A. Sorge and Ronald W. Davis**

Title of Invention: **METHODS OF ENRICHING FOR AND IDENTIFYING  
POLYMORPHISMS**

1. ☒ Specification 125 pages (including specification, claims, abstract) / 144 claims (14 independent)
2. ☒ Declaration/Power of Attorney is:  
☐ attached in the regular manner.  
☒ NOT included, but deferred under 37 C.F.R. § 1.53(f).
3. ☒ This Application has no drawings.
4. ☐ Preliminary Amendment.
5. ☐ Information Disclosure Statement  
☐ Form 1449  
☐ A copy of each cited prior art reference
6. ☐ Assignment with Cover Sheet.
7. ☐ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)

8. ☐ Priority document(s).

09333855, 062399

**NEW UNITED STATES UTILITY PATENT APPLICATION**  
under 37 C.F.R. 1.53(b)

Page 2

Atty. Docket No. 04435/79243

9. ☒ Statement Claiming Small Entity Status is attached.
10. ☐ Microfiche Computer Program (Appendix).
11. ☐ Nucleotide and/or Amino Acid Sequence Submission.  
☐ Computer Readable Copy.  
☐ Paper Copy (identical to computer copy).  
☐ Statement verifying identity of above copies.

12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$760.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	124	18.00	\$2,232.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	11	78.00	\$858.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	1	260.00	\$260.00
Subtotal - Filing Fee Due			\$4,110.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$2,055.00
<b>TOTAL FILING FEE DUE</b>			<b>\$2,055.00</b>
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
<b>GRAND TOTAL DUE</b>			<b>\$2,055.00</b>

13. PAYMENT is:

- ☐ included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18.
- ☒ not included, but deferred under 37 C.F.R. § 1.53(f).

14. All correspondence for the attached application should be directed to:

Kathleen Madden Williams  
Banner & Witcoff, Ltd.  
28 State Street, 28th Floor  
Boston, MA 02109  
Telephone: (617) 227-7111  
Facsimile: (617) 227-4399

[illegible]

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney's Docket No. 04435/79243)

Applicant or  
 Patentee: Joseph A. Sorge and Ronald W. Davis  
 Serial or  
 Patent No. Not Yet Assigned Filed or  
 Issued: Herewith  
 Title: METHODS OF ENRICHING FOR AND IDENTIFYING POLYMORPHISMS

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS**  
**(37 CFR § 1.9(f) AND § 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Stratagene  
 ADDRESS OF CONCERN 11011 North Torrey Pines Road  
La Jolla, CA 92037

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR §121.12, and reproduced in 37 CFR § 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled Methods of Enriching for and Identifying Polymorphisms

by inventor(s) Joseph A. Sorge and Ronald W. Davis  
 described in \_\_\_\_\_

- ☒ the specification filed herewith  
☐ Application Serial No. \_\_\_\_\_ filed \_\_\_\_\_  
☐ Patent No. \_\_\_\_\_ issued \_\_\_\_\_

062359 55333333

If the rights held by the above identified small business concern are not exclusive, each individual concern or organization having rights in the invention must file verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR § 1.9(d), or a nonprofit organization under 37 CFR § 1.9(e).

Each person, concern or organization having any rights to the invention is listed below:

☐ No such person, concern or organization exists.

☒ Each such person, concern or organization is listed below.

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual

☐ Small Business Concern

☐ Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual

☐ Small Business Concern

☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights in the invention averring to their status as small entities. (37 CFR § 1.27).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing therein, or any patent to which this verified statement is directed.

Ronni L. Sherman

NAME OF PERSON SIGNING

Executive Vice President and General Counsel

TITLE IN ORGANIZATION

11011 North Torrey Pines Road, La Jolla, CA 92037

ADDRESS OF PERSON SIGNING

Signature

Date

09338855 "558888880

## METHODS OF ENRICHING FOR AND IDENTIFYING POLYMORPHISMS

### ABSTRACT OF THE DISCLOSURE

The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample. Methods also are disclosed for enriching for and identifying a polymorphism by contacting a nucleic acid sample that includes a subset of nucleic acid molecules having a sequence that binds to a sequence-specific binding activity with a molecule having a sequence-specific binding activity under conditions which permit specific binding, such that the subset of nucleic acid molecules bound to the activity is enriched for nucleic acid molecules having the sequence recognized by the sequence-specific binding activity, and detecting a polymorphism with respect to a reference sequence in the subset of nucleic acid molecules.

## FIELD OF THE INVENTION

The present invention relates in general to nucleic acid sequence analysis, and in particular to methods which facilitate the identification of sequence polymorphisms.

## BACKGROUND OF THE INVENTION

5           Genomic amplification strategies using the polymerase chain reaction (PCR; Mullis & Faloona, 1987, Meth. Enzymol. 155:335) are employed to facilitate the identification of polymorphic sequences. PCR is used to amplify regions of genomic DNA that carry potential polymorphisms. One method hybridizes the PCR products to allele-specific hybridization probes (Saiki et al., 1986, Nature 324:163). Other methods utilize oligonucleotide primers  
10       that either match or mismatch the targeted polymorphism (Newton et al., 1989, Nucleic Acids Res. 17:2503).

          With methods that hybridize the PCR product to an allele-specific probe, PCR is used to reduce the complexity of the DNA sample being assayed for the polymorphic marker and to increase the number of copies of the polymorphism-bearing DNA. If 100,000 polymorphic  
15       markers were to be assayed per genome, it would be very expensive to perform 100,000 individual PCR reactions. Some advances have been made to multiplex PCR reactions (Chamberlain et al., 1988, Nucl. Acids Res. 16:11141), and the degree of multiplexing of the PCR has been scaled up, followed by hybridization to an array of allele-specific probes (Wang et al., 1998, Science 280: 1077). However, in the studies by Wang et al., the  
20       percentage of PCR products that successfully amplified decreased as the number of PCR primers added to the reaction increased. When approximately 100 primer pairs were used,

about 90% of the PCR products were successfully amplified. When the number of primer pairs was increased to about 500, about 50% of the PCR products were successfully amplified. Another disadvantage with multiplex PCR is that individual primer pairs must be synthesized for each polymorphic target. Genotyping DNA with 100,000 polymorphism targets would require, in theory, 200,000 different PCR primers. Not only is the synthesis of such primers costly and time consuming, but not all primer designs succeed in producing a desired PCR product. Therefore considerable time and energy may be spent optimizing the primer designs.

Hatada et al. have cleaved genomic DNA with a rarely cutting restriction enzyme, separated the cleaved DNA by gel electrophoresis, again cleaved the separated DNA with a second restriction enzyme in the gel, and again separated the DNA in a second dimension by electrophoresis (Hatada et al., 1991, Proc. Natl. Acad. Sci. USA 88: 9523). According to the Hatada et al. method, one then examines the two-dimensional pattern of DNA spots using DNA from different individuals. Differences in DNA migration patterns result from sequence or nucleotide methylation differences in the restriction enzyme recognition sequences.

Hayashizaki et al. (Hayashizaki et al., 1992, Genomics 14:733) use solid-phase adapters specific for restriction fragment ends to physically separate a subset of fragments from genomic DNA. After purification of the adapter-bound DNA fraction away from the rest of the genomic DNA, the bound DNA is separated from the adapters by cleaving again with the restriction enzyme used for the adapter ligation. The DNA released from the adapters is then cloned into a replication vector to make a gene library.



Others have used DNA binding factors to reduce the complexity of populations of synthetic oligonucleotides with stretches of randomized sequences, with the aim of elucidating the consensus binding sequences of the proteins (Mavrothalassitis et al., 1990, DNA Cell Biol., 9:783; Blackwell & Weintraub, 1990, Science, 250: 1104; Woodring et al., 1993, Trends Biol. Sci., 18: 77; Hardenbol & Van Dyke, 1996, Proc. Natl. Acad. Sci. U.S.A., 93: 2811).

There is a need in the art for improved methods of identifying polymorphic sequences.

#### SUMMARY

The invention encompasses a method of enriching for and identifying a nucleic acid sequence difference with respect to a reference sequence comprising: a) contacting a nucleic acid sample with a molecule comprising a sequence-specific binding activity under conditions which permit specific binding, wherein the sample comprises a subset of nucleic acid molecules having a sequence that binds to the sequence-specific binding activity, and wherein a bound subset of nucleic acid molecules is retained by the sequence-specific binding activity, such that the subset of bound nucleic acid molecules is enriched for molecules comprising the sequence recognized by the sequence-specific binding activity; and b) detecting a sequence difference with respect to a reference sequence in the subset of nucleic acid molecules.

In a preferred embodiment of the invention, the molecule comprising sequence-specific binding activity is selected from the group consisting of: transcription factors or

66229 " 5933360  
DNA binding domains thereof; proteins with zinc-finger DNA binding domains; restriction  
endonuclease DNA recognition domains; sequence-specific antibodies; oligonucleotides  
complementary to an adapter ligated to a population of DNA molecules; nucleic acid  
molecules; aptamers; peptide nucleic acid molecules; peptides; and affinity resins which  
5 recognize DNA having a particular G+C content or methylation status.

In a preferred embodiment of the invention, the sequence-specific binding activity is  
bound to a solid support.

The invention also encompasses a method of identifying nucleic acid sequence  
differences with respect to a reference sequence comprising: a) cleaving a nucleic acid  
10 sample from one or more individuals with one or more sequence-specific cleavage agents to  
produce nucleic acid fragments; b) operatively linking the fragments of step (a) with  
molecules capable of being replicated; c) introducing the linked molecules of step (b) into a  
system capable of replicating only a subset of the linked molecules, and replicating the subset  
to form a collection of replicated molecules; and d) detecting one or more nucleic acid  
15 sequence differences with respect to a reference sequence in the members of the collection of  
step (c) with a method capable of detecting one or more nucleotide differences with respect to  
a reference sequence.

In a preferred embodiment, the system capable of replicating the linked molecules  
comprises host cells and the collection of replicated molecules comprises a library.

20 In a preferred embodiment, the method capable of detecting one or more nucleotide  
differences comprises DNA sequencing.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the  
5 nucleic acids.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

In a preferred embodiment, the sequencing is performed using primers that hybridize  
10 to the molecules capable of being replicated.

In a preferred embodiment, the system capable of replicating the linked molecules comprises in vitro replication of the linked molecules.

In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to the molecules capable of being  
15 replicated.

In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising both a segment of the molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to the molecules capable of being replicated.

20 In a preferred embodiment, the one or more cleavage agents may be one or more restriction endonucleases. It is preferred that at least one of the restriction endonuclease cleaves DNA infrequently.

In a preferred embodiment, the infrequently cleaving restriction endonuclease is selected from the group consisting of AscI, BssHII, EagI, NheI, NotI, PacI, PmeI, RsrII, Sall, SbfI, SfiI, SgrAI, SpeI, SrfI, and SwaI restriction endonucleases.

The invention also encompasses a method of identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) cleaving a nucleic acid sample from one or more individuals with one or more sequence-specific cleavage agents to produce nucleic acid fragments, wherein the ends of only a subset of the fragments comprise sequences capable of being operatively linked to a separation element; b) operatively linking the subset of step (a) with the separation element; c) separating the linked molecules; and d) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of the separated molecules of step (c) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

In a preferred embodiment, the sequencing is performed using primers that hybridize to the sequences capable of being operatively linked to a separation element.

In a preferred embodiment, the one or more cleavage agents are one or more restriction endonucleases. It is preferred that at least one restriction endonuclease cleaves DNA infrequently.

In a preferred embodiment, the infrequently cleaving restriction endonuclease is selected from the group consisting of *AscI*, *BssHII*, *EagI*, *NheI*, *NotI*, *PacI*, *PmeI*, *RsrII*, *SalI*, *SbfI*, *SfiI*, *SgrAI*, *SpeI*, *SrfI*, and *SwaI* restriction endonucleases.

The invention also encompasses a method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) fragmenting a nucleic acid sample from one or more individuals to an average fragment length; b) physically separating a subset of the nucleic acid fragments generated in step (a) based on the presence or absence of a particular nucleotide sequence within the fragments; c) operatively linking the subset of step (b) with molecules capable of being replicated; d) introducing the linked molecules of step (c) into a system capable of replicating the linked molecules, and replicating the linked molecules to form a collection of replicated molecules; and e) detecting a nucleic acid sequence difference with respect to a reference sequence in the collection of replicated molecules of step (d) using a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

In a preferred embodiment, the system capable of replicating the linked molecules comprises host cells and the collection of replicated molecules comprises a library.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

- 5 In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

- In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of  
10 nucleic acid.

In a preferred embodiment, the DNA sequencing is performed using primers that hybridize to the molecules capable of being replicated.

In a preferred embodiment, the system capable of replicating the linked molecules comprises in vitro replication of the linked molecules.

- 15 In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to the molecules capable of being replicated.

- In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising both a  
20 segment of the molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to the molecules capable of being replicated.

In a preferred embodiment, the in vitro replication is repeated one or more times to increase the enrichment of the linked molecules.

In a preferred embodiment, the method used to physically separate a subset of fragments comprises using a sequence-specific binding molecule.

5 In a preferred embodiment, the sequence-specific binding molecule is a protein.

In a preferred embodiment, the one or more cleavage agents are restriction endonucleases.

The invention also encompasses a method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) fragmenting a  
10 nucleic acid sample from one or more individuals to an average fragment length; b)  
separating a subset of the nucleic acid fragments based on the presence or absence of a  
nucleotide sequence within the fragments; c) detecting one or more nucleic acid sequence  
differences with respect to a reference sequence in the members of the separated molecules of  
step (b) with a method capable of detecting one or more nucleotide differences with respect  
15 to a reference sequence.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

20 In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

5 In a preferred embodiment, the DNA sequencing is performed using primers that hybridize to the molecules capable of being replicated.

In a preferred embodiment, the method used to physically separate a subset of fragments comprises using a sequence-specific binding molecule.

In a preferred embodiment, the sequence-specific binding molecule is a protein.

10 The invention also encompasses a method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) hybridizing a nucleic acid sample from one or more individuals with oligonucleotide primers under conditions wherein each of the primers permits extension by a polymerase of two or more different sequences, and wherein the sequences replicated by extension of the primers comprise regions where there are known sequence differences between individuals of the  
15 species being examined; b) extending the oligonucleotide primers hybridized in step (a) to form an enriched collection of replicated molecules; and c) detecting one or more nucleic acid sequence differences in the members of the collection with respect to a reference sequence with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

20 In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.



In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the  
5 nucleic acids.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

In a preferred embodiment, the DNA sequencing is performed using primers that  
10 hybridize to the primers hybridized in step (a) and extended in step (b).

In a preferred embodiment, steps (a) and (b) are repeated one or more times to increase the enrichment of the enriched collection of replicated molecules.

In a preferred embodiment, the method further comprises, after step (b) and before step (c) the step of hybridizing a second set of primers that hybridize specifically to  
15 sequences comprising both a segment of the first set of primers and a segment of the replicated portion of the molecules generated in step (b).

The invention also encompasses a method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) fragmenting a nucleic acid sample from one or more individuals; b) physically separating a subset of the  
20 nucleic acid fragments based on the size of the fragments; c) operatively linking the subset of step (b) with molecules capable of being replicated; d) introducing the linked subset of molecules of step (c) into a system capable of replicating the linked subset of molecules, and

replicating the subset of linked molecules to form an enriched collection of replicated molecules; and e) detecting one or more nucleotide sequence differences in the members of the collection of step (d) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

- 5           In a preferred embodiment, the system capable of replicating the linked molecules comprises host cells and the collection of replicated molecules comprises a library.

          In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.

- In a preferred embodiment, the method capable of detecting one or more nucleotide  
10 differences comprises denaturing HPLC.

          In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

- In a preferred embodiment, the method capable of detecting one or more nucleotide  
15 differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

          In a preferred embodiment, the sequencing is performed using primers that hybridize to the molecules capable of being replicated.

- In a preferred embodiment, the system capable of replicating the linked molecules  
20 comprises in vitro replication of the linked molecules.

In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to the molecules capable of being replicated.

In a preferred embodiment, the in vitro replication is repeated one or more times to  
5 increase the enrichment of the collection of replicated molecules.

In a preferred embodiment, the in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising both a segment of the molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to the molecules capable of being replicated.

10 In a preferred embodiment, the physical separation by size of step (b) is accomplished using electrophoresis, density gradient centrifugation, or centrifugation through a viscous solution.

The invention also encompasses a method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising: a) fragmenting a  
15 nucleic acid sample from one or more individuals; b) physically separating a subset of the nucleic acid fragments based on the size of the fragments; c) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of the separated molecules of step (b) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

20 In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises DNA sequencing.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the  
5 nucleic acids.

In a preferred embodiment, the method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

In a preferred embodiment, the physical separation by size is accomplished using  
10 electrophoresis, density gradient centrifugation, or centrifugation through a viscous solution.

The invention also encompasses a method for accessing a sub-portion of a nucleic acid population, such method comprising: a) mixing one or more oligonucleotide primers with a sample of the nucleic acid population under conditions which permit hybridization of one or more primers to the sample, each primer comprising a 3' terminal sequence which  
15 hybridizes to an anchor sequence present in the nucleic acid sample; and wherein the one or more oligonucleotide primers contains an additional 3'-terminal extension immediately adjacent to the sequence which hybridizes to an anchor sequence; and b) adding ribonucleotides or deoxynucleotides and a template-dependent polymerizing activity under conditions which permit extension of the one or more oligonucleotide primers, such that the  
20 population of extended primers comprises a sub-portion of nucleic acid molecules in the sample.

In a preferred embodiment, the primer comprises an additional 3'-terminal extension immediately adjacent to the sequence which hybridizes to an anchor sequence.

In a preferred embodiment, the additional 3' terminal extension is selected from the group consisting of G, A, T and C.

5 In a preferred embodiment, the additional 3' terminal extension is selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

In a preferred embodiment, the additional 3' terminal extension is a trinucleotide selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT;  
10 ACA; ACC; ACG; ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

In a preferred embodiment, the additional 3' terminal extension is selected from the  
15 group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

In a preferred embodiment, the anchor sequence is the recognition sequence for a sequence-specific DNA binding activity selected from the group consisting of: transcription factors or DNA binding domains thereof; proteins with zinc finger DNA binding domains;  
20 restriction endonuclease DNA sequence recognition domains; sequence-specific antibodies; nucleic acid molecules; oligonucleotides complementary to an adapter ligated to a population

of DNA molecules; aptamers; peptide nucleic acid molecules; peptides; and affinity resins which recognize DNA having a particular G+C content or methylation status.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to between about 500 and 5000  
5 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 500 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is  
10 added sufficient to limit the average extension product to approximately 750 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is  
15 added sufficient to limit the average extension product to approximately 1500 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 2000 nucleotides in  
20 length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 3000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 4000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 5000 nucleotides in length.

In a preferred embodiment, the anchor sequence is a restriction endonuclease recognition sequence.

In a preferred embodiment, the restriction endonuclease recognition sequence occurs infrequently in the genome of the organism from which the nucleic acid sample is obtained.

In a preferred embodiment, the restriction endonuclease recognition sequence that occurs infrequently in the genome of the organism from which the nucleic acid sample is obtained is selected from the group consisting of: *AscI*, *BssHII*, *EagI*, *NheI*, *NotI*, *PacI*, *PmeI*, *RsrII*, *Sall*, *SbfI*, *SfiI*, *SgrAI*, *SpeI*, *SrfI*, and *SwaI* restriction endonuclease recognition sequences.

In a preferred embodiment, one or more of the oligonucleotides or deoxynucleotides is detectably labeled.

In a preferred embodiment, the label is selected from the group consisting of: fluorescent moieties; radioactive moieties; biotin; and digoxigenin.

In a preferred embodiment, the oligonucleotide primer or primers is/are attached to a solid support or is/are labeled with a moiety allowing attachment to a solid support.

In a preferred embodiment, the method of accessing a sub-portion of a nucleic acid population comprises the additional step of identifying a nucleic acid sequence

5 polymorphism in a population of individuals.

In a preferred embodiment, the method of accessing a sub-portion of a nucleic acid population comprises the additional step of genotyping an individual with respect to a nucleic acid sequence polymorphism.

66E290"55BEE60

The invention also encompasses a method for accessing a sub-population of a

10 genome, such method comprising: a) cleaving a nucleic acid sample with a first restriction endonuclease wherein the recognition sequence of the first restriction endonuclease occurs infrequently in the genome; b) ligating an adapter molecule to the cleaved ends generated in step (a), the adapter having an overhang complementary to that generated by the first

15 restriction endonuclease, and ligation of the adapter further fully or partially regenerating the recognition sequence of the first restriction endonuclease; c) mixing an oligonucleotide primer complementary to the adapter molecule, wherein the 3' terminus of the

oligonucleotide primer is complementary to the fully or partially regenerated recognition sequence of the first restriction endonuclease, under conditions which permit hybridization of the oligonucleotide primer to the adapter; and d) adding nucleotides and a template-

20 dependent polymerizing activity under conditions which permit extension of the oligonucleotide primer, the resulting population of primer extension products comprising a sub-portion of the molecules in the nucleic acid sample.



5 The invention also encompasses a method for accessing a sub-population of a genome, such method comprising: a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments; b) mixing one or more primers capable of annealing to nucleic acid fragment ends generated by the one or more cleavage agents and capable of initiating the replication of the nucleic acid regions comprising the fragment ends under conditions that permit the annealing; c) incubating with a polymerizing activity under conditions that permit extension of the one or more primers, the resulting population of primer extension products comprising a sub-portion of the nucleic acid sequences in the genome, wherein the sub-portion of the nucleic acid sequences comprises an incomplete extension product.

In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents.

15 In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents and the primers comprise sequences complementary to the recognition sequence of the sequence-specific cleavage agents.

In a preferred embodiment, the primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.

It is preferred that the 3' end sequences comprise terminal extensions immediately adjacent to the sequence that hybridizes to the recognition sequence.

20 It is also preferred that the terminal extensions are mononucleotides selected from the group consisting of: A, C, G, and T.

It is also preferred that the extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

It is also preferred that the extensions are trinucleotides selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT;  
5 ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC;  
CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT;  
GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC;  
TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

In a preferred embodiment, the extension is selected from the group consisting of:  
10 tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

It should also be appreciated by one skilled in the art that the adapter molecules that are operatively linked to the cleaved ends of nucleic acids may comprise a promoter sequence capable of initiating the synthesis of RNA or DNA from the promoter site with an appropriate polymerase. For example, the adapter may comprise a T7 RNA polymerase promoter  
15 oriented so that transcription will proceed into the nucleic acid sample to which the adapter has been operatively linked.

The invention also encompasses a method for accessing a sub-population of a genome, such method comprising: a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments; b) operatively linking an adapter molecule  
20 to the cleaved ends generated in step (a); c) incubating with a polymerizing activity under conditions that permit nucleic acid synthesis from the adapter, the resulting population of extension products comprising a sub-portion of the nucleic acid sequences in the genome,

wherein the sub-portion of the nucleic acid sequences comprises an incomplete extension product.

In a preferred embodiment, the adapter molecule contains a transcriptional promoter.

In a preferred embodiment, the adapter molecule contains a free end capable of being  
5 extended by a polymerizing activity.

In a preferred embodiment, the adapter molecule is double stranded and contains a sequence capable of being nicked by a second cleavage agent to produce a free end capable of being extended by a polymerizing activity.

The invention also encompasses a method for accessing a sub-population of a  
10 genome, such method comprising: a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments; b) operatively linking an adapter molecule to the cleaved ends generated in step (a); c) mixing a primer complementary to the adapter molecule with the linked molecules generated in step (b) under conditions that permit hybridization of the primer to the adapter; and d) incubating with a polymerizing activity  
15 under conditions that permit nucleic acid synthesis from the adapter, the resulting population of primer extension products comprising a sub-portion of the genome, wherein the sub-portion of the genome comprises an incomplete extension product.

In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents.

20 In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents and the primers comprise sequences complementary to the recognition sequence of the sequence-specific cleavage agents.

In a preferred embodiment, the primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.

It is preferred that the 3' end sequences comprise terminal extensions immediately adjacent to the sequence that hybridizes to the recognition sequence.

5 It is also preferred that the terminal extensions are mononucleotides selected from the group consisting of: A, C, G, and T.

It is also preferred that the extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

It is also preferred that the extensions are trinucleotides selected from the group  
10 consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

15 In a preferred embodiment, the extensions are selected from the group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

The invention also encompasses a method for accessing a sub-population of a genome, such method comprising: a) cleaving a nucleic acid sample with a cleavage agent; b) operatively linking an adapter molecule to the cleaved ends generated in step (a), the adapter  
20 having an end compatible with that generated by the cleavage agent; c) mixing a primer complementary to the adapter molecule, wherein the 3' terminus of the primer is complementary to the recognition sequence of the cleavage agent, under conditions that

permit hybridization of the primer to the adapter; and d) adding nucleotides and a template-dependent polymerizing activity under conditions that permit extension of the oligonucleotide primer, the resulting population of primer extension products comprising a sub-portion of the genome.

- 5            In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents.

          In a preferred embodiment, the one or more cleavage agents are sequence-specific cleavage agents and the primers comprise sequences complementary to the recognition sequence of the sequence-specific cleavage agents.

- 10           In a preferred embodiment, the primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.

          It is preferred that the 3' end sequences comprise terminal extensions immediately adjacent to the sequence that hybridizes to the recognition sequence.

- It is also preferred that the terminal extensions are mononucleotides selected from the  
15    group consisting of: A, C, G, and T.

          It is also preferred that the extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

- It is also preferred that the extensions are trinucleotides selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT;  
20    ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC;  
          CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT;

GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

In a preferred embodiment, the extensions are selected from the group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

5 In a preferred embodiment, an amount of chain-terminating deoxynucleotide analogs is added sufficient to limit the length of the average extension product to between about 500 and 5000 nucleotides.

10 In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 500 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 750 nucleotides in length.

15 In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1500 nucleotides in length.

20 In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 2000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 3000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 4000 nucleotides in length.

In a preferred embodiment, an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 5000 nucleotides in length.

In a preferred embodiment, the oligonucleotide primer or one or more of the deoxynucleotides is detectably labeled. In a preferred embodiment, the label is selected from the group consisting of fluorescent moieties, radioactive moieties, biotin and digoxigenin.

In a preferred embodiment, the oligonucleotide primer is attached to a solid support.

In a preferred embodiment, the method for accessing a sub-population of a genome comprises the additional step of identifying a nucleic acid sequence polymorphism in a population of individuals.

In a preferred embodiment, the method of accessing a sub-population of a genome comprises the additional step of genotyping an individual with respect to a nucleic acid sequence polymorphism.

As used herein, the term "nucleotide sequence" refers to a consecutive linear arrangement of nucleotide bases at least two nucleotides in length on a nucleic acid molecule.

As used herein, the term “reference sequence” refers to a sequence in the genome which is selected as a standard for sequence comparison. The standard is selected based on a sequence containing a nucleotide at one position in the reference sequence or nucleotides at a number of positions in the reference sequence which represent those nucleotides found most frequently at those positions in two or more individuals, or in a population or in a species. A reference sequence also may refer to a sequence selected from an individual and used for comparison to the sequence of another one or more individuals.

As used herein, the term “sequence difference” refers to one or more nucleotide differences in a given sequence with respect to a reference sequence.

As used herein, the term “nucleic acid sample” refers to a sample containing nucleic acid molecules including a sample comprising genomic, cDNA, mitochondrial, chloroplast, or RNA nucleic acids, a sample comprising nucleic acids expressed by a given tissue or cell type, or a sample comprising nucleic acids produced by replication of nucleic acids expressed by a given tissue or cell type. The term “nucleic acid sample” as used herein does not encompass synthetic random sequence DNA or RNA.

As used herein, the term “sequence-specific binding activity” refers to an activity that binds with a particular nucleic acid sequence or sequence motif. Depending upon the particular activity, a sequence-specific binding activity may bind a single, invariant sequence, or it may bind two or more variant sequences with conserved nucleotides at particular positions.

As used herein, the term “separation element” refers to a moiety that can facilitate the separation of a sub-population of nucleic acid molecules from a larger population of nucleic



acid molecules based upon recognition of a specific sequence. A separation element according to the invention comprises a sequence-specific binding activity which is either immobilized or capable of being immobilized so as to effect separation of bound nucleic acid molecules.

5           As used herein, the term "sequence that is bound by a sequence-specific binding activity" refers to the particular sequence or sequence motif bound by a particular sequence-specific binding activity. As used herein, the terms "anchor" or "anchor sequence" and "marker sequence" are equivalent to "sequence that is bound by a sequence-specific binding activity.

10           According to the invention, such a sequence occurs at least twice, but can occur, for example, 3, 4, 5, 10, 20, 50, 100, 1000, 10,000, 25,000, 50,000 or even 100,000 times or more per genome, and can be selected for or enriched relative to regions of the genome where such sequences are absent or present in lower abundance.

          As used herein, the term "enrichment" or "enrichment of genetic markers" refers to  
15   the result of any process which increases the concentration of any particular nucleic acid sequence (genetic marker) relative to some other nucleic acid sequence as compared to a sample not subjected to the process. As used herein, a nucleic acid sample is considered to be enriched for a particular marker if the marker is in greater concentration relative to the average concentration of all markers than in a sample which has not been subjected to an  
20   enrichment process; for example, where the marker is present in the enriched sample at a concentration 5-fold greater than in the unenriched sample. As used herein, the "complexity" of a DNA sample refers to the number of different unique sequences present in that sample.

As used herein, a sample is considered to have “reduced complexity” if it is less complex (for example, in the range of 5-fold to 10-fold, inclusive, less complex) than the DNA sample from which it is derived.

As used herein, “solid support” refers to a solid or semisolid material which has the property, either inherently or through attachment of some component conferring the property (e.g., an antibody, streptavidin, nucleic acid, or other affinity partner), of binding to a nucleic acid or polypeptide. Such binding can be direct, or may be mediated by a label (e.g., biotin, a nucleic acid sequence tag, or other affinity partner) attached to the nucleic acid or polypeptide. Examples of solid supports include, but are not limited to nitrocellulose and nylon membranes, agarose or cellulose based beads (e.g., Sepharose) and paramagnetic beads.

As referred to herein, the term “cleavage agent” refers to an agent or molecule having an activity that cuts a nucleic acid molecule. It should be understood that a cleavage agent as used herein may cleave one or both strands of a double-stranded nucleic acid molecule.

As used herein, the term “sequence-specific cleavage agent” refers to a cleavage agent that requires or recognizes the presence of a particular nucleic acid sequence, or “recognition sequence” for cleavage to occur. A sequence-specific cleavage agent may cleave the nucleic acid either within the recognition sequence or at a point removed from the recognition sequence on the same molecule.

As used herein, the term “subset of fragments” or “subset of molecules” refers to that fraction of a population of nucleic acid fragments, less than every molecule in the population,

having a given characteristic (e.g., having ends capable of annealing to a particular linker or primer, or having a particular average length).

As used herein, the term “sequences capable of being operatively linked” refers to nucleic acid sequences that can be annealed to another particular nucleic acid sequence by Watson:Crick hydrogen bonded base pairing, or annealed and ligated. However, covalent attachment is not always necessary for there to be an operative linkage.

As used herein, the term “molecule capable of being replicated” refers to a nucleic acid molecule that permits the synthesis or polymerization of copies or replicas of itself or a nucleic acid molecules linked to it. As used in this context, a complementary strand of a nucleic acid falls within the meaning of the term “replica”. The term “molecule capable of being replicated” includes, but is not limited to, an oligonucleotide or a plasmid.

As used herein, the term “system capable of replicating said linked molecules” refers to the components (such as oligonucleotide primers and a template-dependent nucleic acid polymerizing activity, or host cells) necessary for in vitro or in vivo generation of a copy or replica of a molecule either annealed or linked to a molecule capable of being replicated.

As used herein, the term “library” refers to a collection of nucleic acid sequences linked to nucleic acid molecules that permit the replication of the members of the collection within host cells.

As used herein, the term “hybridize specifically” means that nucleic acids hybridize with a nucleic acid of complementary sequence. As used herein, a portion of a nucleic acid molecule may hybridize specifically with a complementary sequence on another nucleic acid molecule. That is, the entire length of a nucleic acid sequence does not necessarily need to

hybridize for a portion of such a sequence to be considered “specifically hybridized” to another molecule; there may be, for example, a stretch of nucleotides at the 5'-end of a molecule that do not hybridize while a stretch at the 3' end of the same molecule is specifically hybridized to another molecule.

5           As used herein, the term “infrequently,” as applied to cleavage of mammalian DNA (e.g. human DNA) by a restriction endonuclease refers to cleavage which occurs 300,000 times or less in a given genome (for example, 250,000, 200,000, 150,000, or 100,000 times) or which generates an average fragment size of 10,000 bp or more (for example, 20,000 bp, 30,000 bp, 50,000 bp) when a given genomic DNA sample is digested. These frequencies are  
10 particularly applicable to human DNA. Restriction endonucleases that generate average fragment sizes of 10,000 base pairs or more on human DNA include, but are not limited to *AscI*, *BssHII*, *EagI*, *NheI*, *NotI*, *PacI*, *PmeI*, *RsrII*, *Sall*, *SbfI*, *SfiI*, *SgrAI*, *SpeI*, *SrfI*, and *SwaI*.

          As used herein, the term “frequently,” or “more frequently” as applied to cleavage of  
15 mammalian DNA by a restriction endonuclease refers to cleavage which occurs more than 300,000 times in a given genome (for example, 500,000-1,000,000 times) or which generates an average fragment size smaller than 10,000 bp (for example, 2,000 bp, 5,000 bp, 8,000 bp) when a given genomic DNA sample is digested. These frequencies are particularly preferred for human DNA.

20           As used herein, the term “average fragment length” refers to a length of nucleic acid molecules in a particular population of nucleic acid molecules which generally is approximately (i.e., within 50-150% of) a predetermined length. In cases where restriction

endonucleases are used to generate fragments of a chosen average fragment length, it should be noted that while the frequency of cutting for a particular sequence may be generally predicted based on the length of the recognition sequence, the base composition of the recognition sequence, and the size or sequence content of the genome, the fragment sizes for

5 a given restriction enzyme may not fall on a bell-shaped curve. In fact, there may be a bimodal or multi-modal distribution. For example, the restriction enzyme recognition sequence may happen to occur in a sequence that is highly repeated in the genome. Such an occurrence will cause there to be a "shoulder" in the normal distribution of fragment lengths. Similarly, if the recognition sequence occurs in two different repeated elements, there will be

10 two "shoulders" in the distribution, etc. In practice, the average size of fragments generated by a given restriction endonuclease may be estimated by examination of fragments after electrophoretic separation on a gel. One should recognize, however, that larger fragments stain more intensely than do shorter fragments on such a gel.

As used herein, the term "genotyping an individual with respect to a nucleic acid

15 sequence polymorphism" refers to the identification of the nucleic acid sequence of an individual at a site known to have one or more polymorphisms in a population of other individuals. Within this context a "population of other individuals" can be one or more other individuals.

As used herein, the terms "sub-population of a genome" or "sub-portion of a genome"

20 refer to a collection of nucleic acids derived from a genomic nucleic acid sample wherein the collection does not substantially contain sequences representative of the entire genome.

As used herein, the term “incomplete extension product” refers to the nucleic acid products of primers or promoters extended by a template-dependent nucleic acid polymerizing activity in which polymerization proceeded over less than the full length of the template molecule, or in the case where there is a primer binding site or promoter on both  
5 ends of each template, then less than one half of the length of the template molecule. An incomplete extension product may be 10 nt, 20 nt, 100 nt to 5000 nt or more in length, e.g., 100 nt to 1000 nt, 200 nt to 800 nt, 400 nt to 700 nt, or 500 to 600 nt.

The inventive methods provide significant improvements over prior art methods for identifying nucleotide sequence differences which are currently laborious, relatively  
10 expensive, and time consuming. Genotyping studies useful for pharmacogenomics studies, for example, may involve 100,000 or more polymorphic markers per study subject. The inventive methods provide simplification of the processes for obtaining such markers and decrease the cost of large-scale genotyping efforts. The invention thus provides for identification of polymorphic markers, but also is applicable to any type of genetic marker,  
15 such as (without limitation) tandem repeat sequences, deletions and insertions.

## DETAILED DESCRIPTION

The present invention recognizes that a significant problem encountered in the identification of nucleic acid sequence polymorphisms relates to the complexity of the genome. The invention is predicated upon the observation that a nucleic acid marker

sequence bound by a sequence-specific binding activity may be used to facilitate the identification of polymorphisms.

The human genome is complex. There are approximately 3 billion nucleotides per haploid human genome. A single polymorphic nucleotide must be identified in the presence of 3 billion other nucleotides, requiring an assay with extreme sensitivity and specificity. The invention provides methods that reduce the complexity of the genome or enrich for a particular subset of sequences that will facilitate the identification of sequence polymorphisms.

The invention disclosed herein recognizes that any nucleic acid sequence bound or recognized by a sequence-specific binding activity may be used to reduce the complexity of the genome to facilitate the identification of polymorphisms. The methods disclosed herein solve the genomic complexity problem by identifying and utilizing a marker sequence that can be enriched for with a simple anchored enrichment procedure. Molecules comprising the marker sequence represent a sub-population of the genome or nucleic acid sample having reduced complexity.

Polymorphisms, particularly single nucleotide polymorphisms ("SNPs"), are essentially randomly distributed throughout the genome. The use of the methods of the invention, through the enrichment for molecules bearing a marker sequence, allows substantially reproducible access to substantially similar reduced-complexity sub-populations in different individuals in a population or even in different samples from a single individual. Because polymorphisms are essentially randomly distributed throughout the genome, a number of polymorphic sequences will be present in the reduced-complexity population of

nucleic acid molecules bearing a given marker sequence. Such reduced-complexity sub-populations may then be analyzed to either identify polymorphisms or to determine the genotype of polymorphic loci within that sub-population.

5 A significant advantage of the methods of the invention is that they permit accession of a substantially similar reduced-complexity sub-population of nucleic acid molecules from any individual in a given species. The reduced-complexity sub-population of nucleic acids may then be genotyped with regard to polymorphisms in the sub-population of nucleic acids using any of a number of methods known in the art. The reduced complexity of the nucleic acid population used for genotype analysis allows for an increased signal to background ratio  
10 in the genotyping methods.

15 For example, a DNA molecule carrying a sequence that can be recognized by a sequence-specific binding molecule, such as the DNA binding protein Gal4, can be separated from DNA not carrying the Gal4 sequence. If such DNA is exposed to Gal4 protein which is bound to a solid support, the DNA molecules carrying the Gal4 binding sequence can be separated from other DNA molecules by washing of the Gal4:DNA complexes to remove unbound DNA. If target genomic DNA is first sheared into sub-genome-sized fragments of a desired size and then subjected to a Gal4 protein separation step, any polymorphic markers contained on the Gal4-bound DNA fragments will be enriched relative to markers on DNA fragments not bound by Gal4 protein. The enriched sub-fraction of the genome (sub-  
20 genome) may then be tested for the presence or absence of particular polymorphic alleles through various assays, such as allele-specific hybridization (Saiki, 1986, supra), primer extension (Pastinen et al., 1997, Genome Res. 7: 606), the oligonucleotide ligation assay



(Nickerson et al., 1990, Proc. Natl. Acad. Sci. USA 87: 8923), or the Invader™ assay (Third Wave Technologies; Rosetti et al., 1997, Mol. Cell. Probes 11:155), among others (see below).

Any molecule that binds to a recognition sequence in a nucleic acid can be used to  
5 enrich for molecules bearing a marker sequence. Thus, any sequence bound by a sequence-specific binding activity may be used as a marker according to the invention. For example, DNA binding domains such as found in transcription factors (Jun, Fos, etc.), proteins with zinc-finger DNA binding regions, restriction endonuclease recognition domains, sequence-specific antibodies, nucleic acid molecules, aptamers, peptide nucleic acid (PNA) molecules,  
10 peptides and affinity resins that recognize DNA having particular GC content or methylation status may all be used according to the invention.

Marker sequences facilitate the identification of polymorphic sequences. Any sequence variation between a) two individuals, or between b) an individual and a population of individuals or between c) two populations, or between d) one or more individuals and a  
15 species as a whole may represent a polymorphism. When compared to sequences within the general population, a polymorphism is typically present at a frequency of about 1% or greater, however the term can apply to any sequence variation between two or more individuals in a population, regardless of the frequency. For example, a polymorphism may be present at a frequency of 0.001% (that is, present in at least one individual per 100,000  
20 individuals), 0.01%, 0.1%, 1% or even 10% or more in a given population of individuals.

A polymorphism may be an insertion, deletion, duplication, or rearrangement of any length of a sequence, including single nucleotide deletions, insertions, or base changes

(herein referred to as “single nucleotide polymorphisms” or “SNPs”). A polymorphism, including a SNP, may be neutral or may have an associated variant phenotype. A “neutral polymorphism” is a polymorphism wherein a phenotypic change has not been found in individuals with the sequence variation. A “functional polymorphism” is a sequence  
5 variation that has an associated altered phenotype, and typically occurs at a frequency of greater than or equal to 1% in the population. The term “mutation” generally refers to a genetic change that occurs at a frequency of less than or equal to about 1% in a population, and may, but not necessarily, be associated with a phenotypic change.

The inventive methods, i.e., of discovering polymorphisms are useful, for example, in  
10 the field of pharmacogenomics, which seeks to correlate the knowledge of specific alleles of polymorphic loci with the way in which individuals in a population respond to particular drugs.

A broad estimate is that for every drug, between 10% and 40% of individuals do not respond optimally. Several well known examples (particularly the association of the  
15 response or lack of response to the Alzheimer’s drug Tacrine with one’s genotype at the ApoE locus (Farlow et al., 1998, Neurology, 50: 669) suggest that allelic differences that affect drug absorption, retention, general metabolism and clearance may be involved in these observed differences.

In order to create a response profile for a given drug, the genotype with regard to  
20 polymorphic loci of those individuals receiving the drug must be correlated with the therapeutic outcome of the drug. This is best performed with analysis of a large number of polymorphic loci. Once a genetic drug response profile has been established by analysis of

polymorphic loci in a population, a clinical patient's genotype with respect to those loci related to responses to particular drugs must be determined. Therefore, the ability to identify the sequence of a large number of polymorphic loci in a large number of individuals is critical for both establishment of a drug response profile and for identification of an individual's genotype for clinical applications.

Single nucleotide polymorphisms are, by far, the most prevalent form of genetic polymorphism, and as such, they are useful to correlate drug responses with profiles of individual genetic variation to predict patient responses to drugs. The polymorphisms need not necessarily be in genes related to the particular disease being treated with a given drug.

Rather, in addition to polymorphisms occurring in disease-related genes, useful polymorphisms for establishing drug response profiles can occur in genes or genetic control elements (enhancers, promoters, processing signals and the like) which ultimately have an effect at any step in the metabolism and clearance of the drug or its metabolites. For that matter, useful polymorphisms may simply be closely genetically linked to a gene or control element involved in a drug response, without actually being a part of the coding or regulatory sequences.

#### Reduction of the Complexity of Nucleic Acid Samples Using Marker Sequences

In one embodiment, the method of the invention incorporates the use of a complexity reduction mechanism to both produce the DNA to be used to find polymorphic markers and to reduce the complexity of the DNA template prior to genotyping. Thus, polymorphic sequences are discovered using the marker sequence to enrich a subset of the genome, and the

same enrichment mechanism is used to reduce the complexity of the genome prior to genotyping. In the following discussion, for clarity, the use of sequence-specific binding molecules according to the invention is described. The sequence specific binding molecules are a pair of cleavage agents, the restriction enzymes NotI and EcoRI, which are

5 representative of a combination of two cleavage agents wherein a first agent cleaves genomic DNA infrequently and a second agent cleaves more frequently than the first.

In a preferred embodiment of the method of the invention, the restriction enzymes NotI and EcoRI are first used to cleave human genomic DNA according to standard methods. The doubly cleaved fragments are then ligated into a NotI/EcoRI cloning vector to produce a

10 sub-library of the human genome. The sub-library consists substantially of the DNA flanking most NotI sites. There are approximately 30,000 NotI sites in the human genome. Thus, a library with 1X representation should contain about 60,000 clones. To discover common polymorphisms in this subset of the genome, one would then sequence 60,000 or more clones from libraries constructed from at least one, and preferably several individuals. The DNA

15 sequencing is performed using vector-specific primers, entering the human DNA from the NotI end and the EcoRI end. If DNA from four individuals is used, for example, one would sequence approximately  $60,000 \times 2 \times 4 = 480,000$  segments to achieve a 4X representation around the NotI sites represented in the library. With 4X representation of the NotI/EcoRI sub-genome, one would expect to sequence sample each NotI/EcoRI fragment at least twice

20 for 90.8% of such fragments (1 minus Poisson (0 or 1 with a mean of 4)). One would expect to sample about 57% of the fragments 4 or more times (1 minus Poisson (0,1,2, or 3 with a mean of 4)).

Alternatively, one may also make libraries containing NotI/NotI fragments, and sequence both ends of these. Because the NotI recognition sequence is an 8 bp sequence composed entirely of C and G, such fragments are likely to comprise CpG islands found near transcribed regions of the genome. Thus, the subset of the genome represented by libraries  
5 made using NotI cleavage will likely be biased towards transcribed regions. An advantage of the this particular method, therefore, is that polymorphisms identified from libraries made using NotI will likely fall near or within protein-encoding sequences.

Methods of the invention that utilize library construction or cloning of enriched sequences to replicate enriched populations require the selection of appropriate vector and  
10 host combinations. Vectors and hosts suitable for libraries or other cloning according to the methods of the invention are well known in the art, however preferred attributes of a vector and host for use in the methods of the invention are discussed below.

A sequence selected or enriched according to the methods of the invention may be inserted into a vector in a forward or reverse orientation. A vector may include regulatory  
15 sequences, including, for example, a promoter, operably linked to the sequence. A vector may also contain a gene to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*. The vector may also include an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification  
20 within the host.

The vector containing the DNA sequence enriched as described herein, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host.

Many suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, phagescript, pBluescript SK, pBSKS, LambdaZAP, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, 5 pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmids or other vectors may be used as long as they are replicable and viable in the host.

Promoter regions can be selected from any characterized gene and incorporated into appropriate vectors using techniques well known in the art. Bacterial promoters useful 10 according to the invention include, but are not limited to lacI, lacZ, T3, T7, gpt,  $\lambda P_R$ ,  $\lambda P_L$  and trp. Eukaryotic promoters include, but are not limited to CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

15 A host cell may be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell may be a prokaryotic cell, such as a bacterial cell. Examples of appropriate hosts include but are not limited to: bacterial cells, such as *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be 20 employed as a matter of choice; fungal cells, such as yeast; insect cells such as *Drosophila* and Sf9; animal cells such as CHO, COS or Bowes melanoma; plant cells, etc. The selection of an appropriate host is within the scope of one of skill in the art from the teachings herein.

Introduction of the construct into the host cell can be effected by calcium transfection, DEAE-Dextran-mediated transfection, liposome mediated transfection, or electroporation (Ausubel et al., 1992, Short Protocols in Molecular Biology, 3rd Edition, John Wiley & Sons, Inc., pp. 9-5 to 9-14) in the case of eukaryotic cells.

5 Prokaryotic cells may be made competent to take up foreign DNA by standard methods (Ausubel et al., supra, 1992, pp. 1-22 to 1-23) known in the art. Recombinant constructs may be introduced to bacteria by standard transformation (for plasmids) or transfection/infection (for phage DNA or phage particles; see Ausubel et al., supra, 1992, pp. 1-22 to 1-23).

#### 10 Nucleic Acid Complexity Reduction Methods Useful in the Invention:

The invention contemplates in part the use of complexity reduction and sequence enrichment methods. Complexity reduction reduces the number of unique sequences present in a nucleic acid sample, and enrichment increases the relative concentration of a particular  
15 sequence or subset of sequences in a nucleic acid sample.

A subset of nucleic acid molecules, each containing a sequence bound by a sequence-specific binding activity, is prepared as follows according to the invention. Although cleavage agents are used in the following method, other sequence-specific binding activities may be used according to the invention.

20 The concentration of molecules bearing marker sequences in a population of nucleic acid molecules can be enriched by cleaving genomic DNA with one or more restriction enzymes, and then enriching for a sub-population of the DNA fragments. Genomic DNA can

sequence specific binding activity and the conditions under which such activity functions will be well known prior to its selection for this purpose.

Another method of enriching for molecules with a particular marker sequence involves the use of non-specific PCR or repeat-sequence PCR. Inter-Alu PCR has been used  
5 to amplify a subset of the human genome (Nelson et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6686; Sadhu et al., 1992, Genomics 14: 728). Primers designed to amplify other repeated sequences, such as SINEs and LINEs have also been made (Cotter et al., 1990, Genomics 7:257; Ledbetter et al., 1991, Genomics 8: 475-481). Primers that identify such repeated  
10 repeat sequence, or amplify DNA between different adjacent copies of a repeated sequence. Such complexity reduction and enrichment might allow one to detect markers without prior template amplification, however highly repeated sequences such as Alus, SINES, and LINEs are difficult to differentiate from each other. A marker set contained within such repeat elements would be difficult to locate on a physical map. Moreover, certain markers would be  
15 located in copies of the repeat element that are identical to other copies in the genome (at least in the region being tested for the presence of the marker). However, markers located between repeat elements would be useful. Primers that would amplify the sequences between repeat elements could be used to enrich a population of nucleic acid molecules for sequences containing useful markers.

20 DNA amplification using arbitrary PCR primers produces DNA fragments that are mostly unique in sequence (Welsh & McClelland, 1990, Nucl. Acids Res. 18:7213; Williams et al., 1990, Nucl. Acids Res. 18:6531). Two published methods are respectively called AP-



PCR for arbitrarily primed PCR and RAPD for random amplified polymorphic DNA. AP-PCR generally uses longer PCR primers than RAPD. In both methods, an arbitrary oligonucleotide primer is selected and used to amplify genomic DNA under relatively non-stringent conditions. The primers are extended at multiple locations around the genome, yet

5 yield exponential amplification only in those regions where the primers have hybridized a short distance from another hybridized primer and where both primers are hybridized to opposite strands of the genomic DNA. Multiple arbitrary PCR fragments are produced. The particular fragments are reasonably reproducible from experiment to experiment, provided that similar amplification conditions are used (Schweder et al., 1995, Biotechniques 19:38;

10 Ellsworth et al., 1993, Biotechniques 14: 215). The lengths of such fragments have been analyzed by electrophoresis and used as markers for the presence or absence of particular DNA sequences in the genomic template. PCR fragment differences between individuals or between two chromosomes in a single individual result from polymorphic differences in the template regions to which the arbitrary primers bind. Methods involving the simultaneous

15 use of two arbitrary primers have also been reported to yield consistent fragment patterns (Hu et al., 1995, PCR Methods and Applications 4:346; Desmarais et al., 1998, Nucl. Acids Res. 26:1458).

AP-PCR or RAPD may be used to reduce the complexity of the genome for identification of polymorphisms or for genotyping individuals with respect to the

20 polymorphisms. The major DNA bands seen in a gel electrophoresis of AP-PCR or RAPD products are thought to represent about 15 kilobases of the genome (Desmarais et al., 1998, Nucl. Acids Res. 26: 1458). This is an enormous reduction of the complexity of the human

genome, with sequences present in 15 kilobases roughly equivalent to about 1/1000 of the yeast genome, and 1/200,000 of the human genome. One may thus pool 1000 AP-PCR reactions; the complexity of the resulting product would be about equivalent to the yeast genome. In addition, one may perform less stringent AP-PCR reactions or multiplex the AP-PCR reactions, thereby increasing the percentage of the genome being amplified in one reaction. Fragments most abundant in the mix would be the ones amplified most often. Thus, polymorphisms discovered in this reduced-complexity population tend to be those present on the most abundant fragments in the AP-PCR product.

Ideally, AP-PCR conditions may be adjusted (by varying arbitrary primer length, number of primers, and/or annealing conditions) to amplify about 1/200<sup>th</sup> of the human genome in one tube. This product is about as complex as the yeast genome and may be hybridized directly to allele-specific probes using the methods of Winzeler et al., which can detect polymorphisms in the yeast genome without enrichment (Winzeler et al., 1993, Science 281: 1194). If common polymorphisms occur with a heterozygosity of approximately 1 in 1500 bases, then approximately 10,000 polymorphisms should be present in such a 1/200<sup>th</sup> sub genome from a single individual. Thus, it is possible to genotype 100,000 polymorphisms using about 10 AP-PCR reactions where approximately 1/200<sup>th</sup> of the genome is being amplified per AP-PCR reaction. Each reaction is then hybridized to an array capable of detecting 10,000 different polymorphisms using the methods of Winzeler et al. This greatly decreases the time and expense required to obtain genotypic data from 100,000 polymorphic markers per individual.



the NotI adapters (or anchor-specific adapters) that have been ligated to the genomic DNA. If such primers are designed so that they recognize the NotI adapter sequence and, in one embodiment, also recognize the partial NotI sequence that is ligated to the adapter, they can prime DNA synthesis (by any of a number of enzymes known to those skilled in the art) starting at the NotI ends of the genomic DNA. The complexity of the newly synthesized DNA can be further reduced by including a 3'-terminal extension on the primer immediately adjacent to the NotI recognition sequence. Depending upon the length of the extension, different sized subsets of the population will be capable of extension, and thereby enrichment with concomitant reduction in complexity.

For example, a 3'-mononucleotide extension of G, A, T or C immediately adjacent to the sequence complementary to the marker sequence will allow the extension of roughly one quarter of the sequences bearing the marker sequence, for an approximate 4-fold further reduction in complexity. Similarly, a 3'-terminal dinucleotide extension in any of the 16 possible combinations (AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT, TA, TC, TG, and TT) will allow extension of roughly 1/16th of the sequences bearing the marker sequence, for an approximately 16-fold further reduction in complexity. By the same reasoning, a 3'-terminal trinucleotide extension in any of the 64 possible combinations (AAA, AAC, AAG, AAT, AGA, AGC, AGG, AGT, ACA, ACC, ACG, ACT, ATA, ATC, ATG, ATT, CAA, CAC, CAG, CAT, CCA, CCC, CCG, CCT, CGA, CGC, CGG, CGT, CTA, CTC, CTG, CTT, GAA, GAC, GAG, GAT, GCA, GCC, GCG, GCT, GGA, GGC, GGG, GGT, GTA, GTC, GTG, GTT, TAA, TAC, TAG, TAT, TCA, TCC, TCG, TCT, TGA, TGC, TGG, TGT, TTA, TTC, TTG and TTT) will effect an approximately 64-fold reduction in

complexity. Further reductions may be achieved using 3'-terminal extensions of 4, 5, 6, 7, 8 or more nucleotides immediately adjacent to the sequence complementary to the marker sequence. Using this complexity reduction scheme, one may analyze the entire population, if necessary, through use of primers bearing all 4, 16, 64, 256, etc., possible 3' extensions.

5           Primer extension products made using, for example, dinucleotide-extended primers, are, in theory, 16 fold less complex than the 5% of the genome selected by the NotI/EcoRI method. Not all of the 16 primers will prime with equal efficiency, and some of the primers will be somewhat promiscuous in their priming (for example when G in the primer or  
10           template is opposing T in the template or primer there will be some extension of the primer even though a mismatch occurs between one of the 3' nucleotides of the primer and the template). Overall, however, the primer extension products will be less complex than the NotI/RI subgenome. In this particular case, as well as in cases like it, the primer extension product complexity will be approximately similar to the complexity of the yeast genome, such that the methods of Winzeler, et al. (1993, supra) can be used to detect polymorphisms  
15           in the primer extension products. Alternatively, such DNA synthesized from the 16 different primers (used separately) can be used as a template for other polymorphism genotyping methods as referenced herein (see below).

          For example, genomic DNA may be cleaved with NotI (or another infrequently cleaving cleavage agent), ligated with a NotI- (or other sequence) specific adapter, and then  
20           either used directly for primer extension or further purified. Further purification can be achieved by cleaving the DNA with EcoRI (or other cleavage agent) followed by isolation of the NotI/EcoRI and NotI/NotI fragments using a capture element attached to the NotI

adapters (non-limiting examples include a biotin moiety on the adapter and streptavidin on a solid support or a digoxigenin moiety on the adapter and an anti-digoxigenin antibody on a solid support; conditions for capture, as well as methods for biotin or digoxigenin labeling of oligonucleotides are well known to those skilled in the art). The purified subgenome is then

5 mixed with one of 16 different primers bearing 3'-terminal dinucleotide extensions under conditions permitting primer annealing. These primers will anneal to the NotI adapter sequence and the partial NotI recognition sequence ligated to the adapter. However, only in the approximately 1 out of 16 linked molecules bearing the complement of the 3'-terminal dinucleotide extension adjacent to the NotI sequence will an extension product be generated.

10 The primer-template complexes are then placed into reaction conditions capable of synthesizing DNA (e.g. dNTPs, polymerase, buffer; one set of appropriate conditions is as described herein for PCR, with optimal annealing temperature determined using the formulae also described herein below) and the primers extended from the variable dinucleotide ends to the opposite ends of the template. The primer extension products may be labeled by

15 including one or more labeled dNTPs in the extension reaction. Labels include, but are not limited to radioactive or fluorescent moieties, biotin and digoxigenin. A cycling reaction can be used to linearly amplify the amount of primer extension products, if necessary, for subsequent assays. Labeled primer extension products may then be analyzed for the genotype with respect to particular polymorphisms using, for example, allele-specific hybridization as

20 described herein.

It should be clear to one skilled in the art that purification using some solid phase affinity separation, as outlined above, is not necessary. The DNA can be digested with a

cleavage agent, such as NotI, and ligated with specific adapters. Primers specific for the adapters, the NotI site, and in some cases several nucleotides of the genomic sequence adjacent to the NotI site, can be used to create primer extension products that will be enriched for the regions adjacent to the NotI site. The lengths of such primer extension products can be controlled by adding chain terminating nucleotides to the primer extension mix. The ratio of chain terminating nucleotide triphosphates to normal nucleotide triphosphates will influence the average length of primer extension products. Such primer extension products may either be labeled or unlabeled.

These methods allow the complexity of genomic DNA to be significantly reduced simply through cleavage, annealing and/or ligation, DNA capture (optionally), and a small number (in the example cited, 1 to 16) of primer extension reactions. The methods provide subpopulations of the genome that can be directly analyzed for the presence of polymorphisms with lower background and higher efficiency than methods that do not reduce the complexity of the genomic DNA.

#### Methods of Genotyping Useful in the Invention:

There are a number of methods known in the art that are capable of detecting single nucleotide sequence differences with respect to a reference sequence. Several of these are described below, however it should be understood that any method that allows the determination of the sequence of a particular individual at a particular site may be used to detect sequence differences with respect to a reference sequence in the reduced-complexity nucleic acid populations generated according to the invention.

09338855 "062399  
566399" 588855  
Direct DNA sequencing according to the classical Sanger (dideoxynucleotide sequencing; Sanger et al., 1975, J. Mol. Biol., 94:441) or Maxam & Gilbert (chemical sequencing; Maxam et al., Proc. Natl. Acad. Sci. U.S.A., 1977, 74:560) methods is capable of detecting nucleotide differences according to the invention. In the Sanger method, a primer  
5 that hybridizes to a known sequence on the molecule is extended in the presence of a limiting amount of a chain-terminating nucleoside analog such that a ladder of extension products of different lengths all ending with that nucleotide is generated. Reactions using the same primer with chain-terminating analogs of each of the four dNTPs individually allows determination of the DNA sequence following electrophoresis of the four reactions alongside  
10 each other on the same denaturing gel.

Direct DNA sequencing generally requires amplification of the target sequence. However, marker-based nucleic acid sequence enrichment methods as described herein can raise the template concentration to levels where direct sequencing may be effective in determining a single nucleotide sequence difference.

15 DNA sequencing as necessary for certain embodiments of the invention may also be performed with the Exonuclease Resistance method (Mundy, U.S. Patent No. 4,656,127), primer-guided microsequencing (Kohmer et al., 1989, Nucl. Acids Res., 17:7779), minisequencing (Pastinen et al., 1997, Genome Res., 7: 606), extension in solution using ddNTPs (Cohen et al., French Patent No. 2,650,840; PCT Application No. WO91/02087),  
20 Genetic Bit Analysis<sup>TM</sup> (GBA; Goelet et al., PCT Application No. 92/15712), ligase-polymerase-mediated GBA (Nifikorov et al., U.S. Patent No. 5,679,524) and oligonucleotide ligation assay (OLA; Landegren et al., 1988, Science 241:1077) methods as described below.





polymerase is only able to add one nucleotide to each primer, and this identifies the nucleotide in the template immediately adjacent to the 3' end of the primer, and thus the genotype with respect to the polymorphism. The polymerase reactions can be cycled, such as by thermocycling, to increase the amount of product. After the polymerase extension reactions, the primers are then hybridized to a capture array bearing the various sequences containing the polymorphisms. The spots on the capture array will produce fluorescent signal if the primers were extended with a fluorescently labeled dideoxynucleoside triphosphate. The colors emitted from the spots reveal the alleles present in the target nucleic acid sample. The size of the capture array and the number of primers can be increased as needed.

10           The method using extension in solution and ddNTPs, as described by Cohen et al. (supra) also involves a primer that is complementary to sequences immediately 3' to a polymorphic site. The method determines the identity of the nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide at the polymorphic site will become incorporated onto the terminus of the hybridized primer.

15           Genetic Bit Analysis<sup>TM</sup>, or GBA<sup>TM</sup> is described by Goelet et al. (supra). This method is similar to the method of Cohen et al., except that it is preferably a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase. It is thus easier to perform, more accurate, and better suited for high throughput analyses than the Cohen et al. method.

20           The Oligonucleotide Ligation Assay or OLA was described by Landegren et al. (supra). This is also a solid phase assay using two oligonucleotides designed to be able to hybridize to abutting sequences of a single strand of a target. One of the oligonucleotides is

detectably labeled, and the other is biotinylated. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, creating a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin or another biotin ligand.

5           Ligase/Polymerase-mediated genetic bit analysis, described by Nifikorov et al. (supra), involves the immobilization of a first oligonucleotide to a solid substrate. The immobilized oligonucleotide is incubated with a sample containing the target molecule and with a second oligonucleotide capable of hybridizing to the target molecule such that the two oligonucleotides are separated from one another by the polymorphic site. A polymerase, a  
10   ligase and one deoxynucleoside triphosphate are added. If the nucleotide at the polymorphic site is complementary to the deoxynucleoside triphosphate added, it will become incorporated by the polymerase and create a ligase substrate. Ligation covalently couples the first oligonucleotide to the second oligonucleotide indicating the identity of the polymorphic base.

15           In addition to methods that determine the actual sequence of a polymorphic site, other methods can distinguish between alternative sequences based on differing physical characteristics. These include, but are not limited to, dot-blot hybridization, sequencing by hybridization (SBH), denaturing HPLC, electrophoretic methods capable of distinguishing conformationally different nucleic acid molecules, or binding to proteins capable of detecting  
20   mismatches between duplexed strands of nucleic acids.

          The dot blot method of genotyping with respect to a particular polymorphism involves hybridization analysis using sequence-enriched or amplified DNA (i.e., reduced-

complexity DNA) from an individual and oligonucleotide hybridization probes under conditions which allow discrimination of sequences based on single base pair differences. The reduced-complexity DNA is fixed to hybridization membranes using methods appropriate for the specific membrane type chosen (i.e., nitrocellulose, nylon, etc.). Kafatos et al., 1979, Nucl. Acids Res., 7:1541 describe a method suitable for application of DNA samples to nitrocellulose membrane involving alkaline denaturation and binding in high salt. Individual samples of the enriched, immobilized DNA are then hybridized with labeled oligonucleotides, each bearing one allelic form of the polymorphic site, as described below. (A variation of this approach, the "reverse dot blot" method, uses labeled enriched DNA to probe specific polymorphic oligonucleotides immobilized on a substrate.)

Filters bearing reduced-complexity DNA sequences are pre-hybridized in a solution consisting of 5X SSPE (1X SSPE is 180 mM NaCl, 10 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA), 5X Denhardt's solution (1X Denhardt's solution is 0.02% (w/v) polyvinylpyrrolidone, 0.02% (w/v) Ficoll, 0.02% (w/v) BSA, 0.2 mM Tris-HCl, pH8.0, 0.2 mM EDTA), and 0.5% (w/v) SDS for at least 1 h at 55 C. Radiolabeled probe, or probe detectably labeled by other means, is added to the pre-hybridization mixture and incubated at 55°C for 1 h. Each hybridized filter is then washed twice with 100 ml or more of 2X SSPE, 0.1% SDS for 10 minutes at room temperature. High stringency washes are then performed under temperature and salt conditions such that hybridization is only detected if the probe is 100% complementary to the target sequence. That is, conditions are adjusted so that a single base mismatch will abolish hybridization. Such conditions may be determined by one skilled in the art with a minimum of experimentation necessary for any given polymorphism-containing oligonucleotide.

Generally, the hybridization of shorter oligonucleotides (less than or equal to about 25 nt) is destabilized to a greater extent by single base changes than the hybridization of longer ones. One method to achieve the necessary level of specificity with a minimum of experimentation is to maintain the temperature of the washes constant and vary the salt conditions. Lower salt concentrations are more stringent than high concentrations. Specific examples of this type of hybridization being used to determine the genotype of an individual with respect to a polymorphism, and the optimization of stringency are described by Ehrlich et al., in the specification of U.S. Patent No. 5,604,099.

Following washing, hybridized signal is detected by exposure to X-ray film, or by other appropriate means dependent on the type of label used (i.e., biotin, digoxigenin, etc.). Because hybridization only occurs if the probe and target sequences are 100% complementary, the presence of a hybridization signal with a particular probe directly indicates that the identity of the polymorphic nucleotide is the complement of the corresponding site on the individual probe used. This method may also be adapted to an array format for high throughput analyses.

SBH (Drmanac et al., 1993, Science, 260(5114): 1649; Drmanac et al., 1998, Nature Biotechnol., 16: 54) involves a strategy of overlapping block reading. It is based on hybridization of DNA with the complete set of immobilized oligonucleotides of a certain length fixed in specific positions on a support. The efficiency of SBH depends on the ability to effectively sort out perfect duplexes from those that are imperfect (i.e. contain base pair mismatches). This is achieved by comparing the temperature-dependent dissociation curves

of the duplexes formed by DNA and each of the immobilized oligonucleotides with standard dissociation curves for perfect oligonucleotide duplexes.

As another example of a method capable of detecting sequence differences based on differing physical characteristics, denaturing high performance liquid chromatography can be used to screen samples for SNPs and other sequence variations (see Ophoff et al., 1996, *Cell*, 87: 543; Underhill et al., 1996, *Proc. Natl. Acad. Sci. U.S.A.*, 93: 196; Underhill et al., 1997, *Virology*, 237: 307; Liu et al., 1998, *Nucleic Acids Res.*, 26: 1396; and O'Donovan et al., 1998, *Genomics*, 52: 44). Alternatively, electrophoretic methods capable of detecting conformational differences in nucleic acids may be used to distinguish polymorphic forms of nucleic acid molecules (see Keen et al., 1991, *Trends Genet.*, 7: 5; White et al., 1992, *Genomics*, 12: 301). As another alternative, one may use a protein capable of detecting mismatches between duplexed strands of nucleic acid (see Parsons & Heflich, 1997, *Mutat. Res.*, 374: 277).

Several embodiments of the invention utilize extension of an annealed primer. This may be accomplished with any of a number of template-dependent polymerases, including, but not limited to Klenow DNA polymerase, Taq DNA polymerase, and AMV or MMLV Reverse Transcriptase. Conditions for primer extension using these polymerases are well known and can be adjusted if necessary for a specific application by one skilled in the art without undue experimentation. See, for example, the following: 1) Klenow DNA polymerase - Kunkel et al., 1987, *Meth. Enzymol.*, 154: 367; 2) Taq DNA polymerase - Gelfand et al., 1990, *PCR Protocols: A Guide to Methods and Applications*, Academic Press, San Diego, CA; and 3) MMLV Reverse Transcriptase - Sambrook et al., 1989, *Molecular*

Cloning: A Laboratory manual, second edition, pp. 5.52-5.55, 8.11-8.17, Cold Spring Harbor Press, Cold Spring Harbor, NY.

It should also be appreciated by one skilled in the art that the adapter molecules that are operatively linked to the cleaved ends of nucleic acids may comprise a promoter sequence capable of initiating the synthesis of RNA or DNA from the promoter site with an appropriate polymerase. For example, the adapter may comprise a T7 RNA polymerase promoter oriented so that transcription will proceed into the nucleic acid sample to which the adapter has been operatively linked (US patents 5,716,785 and 5,891,636). When such adapter-linked molecules are exposed to T7 RNA polymerase under the appropriate conditions, an RNA copy of the nucleic acid sample will be created. The length of the RNA products can be controlled by adding chain-terminating ribonucleotide substrates into the reaction mixture in a concentration that will terminate an average transcript at a certain average length. The RNA products themselves, or a cDNA copy of the RNA products, can then be examined for the presence of the polymorphism.

Conditions for in vitro transcription using, for example, T3, T7 or Sp6 polymerase are well known and can be adjusted as necessary for a specific application by one skilled in the art without undue experimentation. See, for example, the following: 1) T3 RNA polymerase - Leary et al., 1991, Gene, 106:93; 2) T7 RNA polymerase - Bebedck & Kunkel, 1989, Nucleic Acids Res., 17: 5408 and Noren et al., 1990, Nucleic Acids Res., 18: 83; and 3) Sp6 RNA polymerase - Melton et al., 1984, Nucleic Acids Res., 12: 7035.

## EXAMPLES

Example 1. Procedure for the Production of a Human/lambda Library for Identification of Polymorphisms According to the Invention:

5 The following contains an exact step by step description of the procedure utilized in making the four libraries now being used for the identification of SNPs. The procedure being utilized uses lambda ZAP II as the cloning vector. Separate libraries have been made using pBluescript as the cloning vector and other libraries have been made from lambda ZAP II using a slightly different procedure. From the stand-point of the procedure any cloning  
10 vector can be used if it contains the suitable restriction enzyme sites. This procedure utilizes both infrequent cutters of the human genome as well as frequent cutters of the human genome.

The procedure is as follows:

### 1. Lambda Arm Production:

#### Left Arm Production

15 The left arm of lambda ZAP II is isolated by the following procedure. Thirty-five  $\mu\text{g}$  of lambda ZAP II DNA, in 35  $\mu\text{l}$  of TE buffer (10mM Tris-HCl, pH 7.5, 1 mM EDTA- $\text{Na}_2$ ) is added to a tube containing 30  $\mu\text{l}$  of 10x Buffer 2 (250 mM NaCl, 100 mM Tris-HCl (pH 7.5), 100 mM  $\text{MgCl}_2$ , 100 mM  $\beta$ -mercaptoethanol, 300  $\mu\text{g/ml}$  Bovine Serum Albumin (BSA), final concentration). To the tube is added 205  $\mu\text{l}$  of doubly distilled (ds)  $\text{H}_2\text{O}$ . The solution  
20 is mixed by inversion. Finally, 30  $\mu\text{l}$  of the restriction enzyme Hind III (16 Units/ $\mu\text{l}$ , 480 U) are added. The solution is then incubated at 37°C. Following 4 hours of incubation, the solution is heated to 68°C for 15 minutes (min.)



The solution is then extracted twice with an equal volume of phenol followed by extraction once with an equal volume of chloroform. After the extractions, the cut lambda DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The precipitated cut  
5 lambda DNA is isolated by centrifugation at 4°C for 20 min at 14,000-x g. The pelleted cut lambda DNA is then suspended in 75% ethanol and then re-pelleted. Finally, the pelleted cut lambda DNA is dissolved in 140 µl of dsH<sub>2</sub>O.

The dissolved cut lambda DNA is then cut a second time with a different restriction enzyme by the following procedure. To the 140 µl of cut lambda DNA 10 µl of 10X  
10 universal buffer (1 M KOAc, 250 mM Tris-Acetate, pH 7.6, 100 mM MgOAc, 5 mM β-mercaptoethanol, 100 µg/ml BSA, final concentration) and 20 µl of the restriction enzyme Not I (8 U/µl, 160 U) is added. The solution is gently mixed by inversion and then incubated at 37°C for 1 h. Following the incubation, the solution is incubated at 68°C for 15 min.

The solution is then extracted twice with an equal volume of phenol followed by  
15 extraction once with an equal volume of chloroform. After the extractions, the cut lambda DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The pelleted cut lambda is then resuspended in low TE buffer (5 mM Tris-HCl, pH 7.5 and 0.1 mM EDTA-Na<sub>2</sub>, final concentration). The resuspended cut lambda is then quantitated using a  
20 spectrophotometer, measuring absorbance at 260 nm and 280 nm. The left arm of the lambda vector is now ready for its role in the cloning of human genomic DNA.

#### Right Arm Production

The right arm of lambda ZAP II is isolated by the following procedure. Thirty-five  $\mu\text{g}$  of lambda ZAP II, in 35  $\mu\text{l}$  of TE buffer is added to a tube containing 60 $\mu\text{l}$  of 10X universal buffer and 175  $\mu\text{l}$   $\text{dsH}_2\text{O}$ . After mixing the solution by inversion, 30  $\mu\text{l}$  of the restriction enzyme Mlu I (32 U/ $\mu\text{l}$ , 960 U) are added. The solution is then incubated at 37°C for 4 h.

- 5 After the incubation, the solution is heated to 68°C for 15 min.

The solution is then extracted twice with an equal volume of phenol followed by extraction once with an equal volume of chloroform. After the extractions, the cut lambda DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The precipitated cut  
10 lambda DNA is isolated by centrifugation at 4°C for 20 min at 14,000-x g. The pelleted cut lambda DNA is then suspended in 75% ethanol and then re-pelleted. Finally, the pelleted cut lambda DNA is dissolved in 170  $\mu\text{l}$  of  $\text{dsH}_2\text{O}$ .

The dissolved cut lambda DNA is then cut a second time with a different restriction enzyme by the following procedure. To the 170  $\mu\text{l}$  of cut lambda DNA 20  $\mu\text{l}$  of 10X  
15 universal buffer and 10  $\mu\text{l}$  of the restriction enzyme EcoRI (24 U/ $\mu\text{l}$ , 240 U) is added. The solution is gently mixed by inversion and then incubated at 37°C for 1 h. Following the incubation, the solution is incubated at 68°C for 15 min.

The solution is then extracted twice with an equal volume of phenol followed by extraction once with an equal volume of chloroform. After the extractions, the cut lambda  
20 DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The pelleted cut lambda is then resuspended in low TE buffer. The resuspended cut lambda is then

quantitated using a spectrophotometer, measuring at 260 nm and 280 nm. The right arm is now ready for its role in the cloning of human genomic DNA.

#### Preparation of human Genomic DNA for Cloning

Human genomic DNA is prepared for cloning by the following procedure. Twenty µg  
5 of human genomic DNA in 20 µl of TE are added to a tube containing 10 µl of universal  
buffer and 60 µl of dsH<sub>2</sub>O. Ten µl of the restriction enzyme EcoRI (24 U/µl, 240 U) are  
added to the tube. The tube is then incubated at 37°C for 2 h. After the incubation, the  
following is added to the tube: 42 µl of dsH<sub>2</sub>O, 5 µl of 10x universal buffer and 3 µl (171 U)  
of calf intestinal alkaline phosphatase. The tube is then incubated for an additional 30 min at  
10 37°C. Following the incubation, the solution is heated to 68°C for 15 min.

The solution is then extracted twice with an equal volume of phenol followed by  
extraction once with an equal volume of chloroform. After the extractions the cut human  
genomic DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol  
and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The precipitated,  
15 cut human genomic DNA is isolated by centrifugation at 4°C for 20 min at 14,000 x g. The  
pelleted, cut human genomic DNA is then suspended in 75% ethanol and then re-pelleted.  
Finally, the pelleted, cut human genomic DNA is dissolved in 70 µl of dsH<sub>2</sub>O.

The dissolved cut human genomic DNA is then cut a second time with a different  
restriction enzyme by the following procedure. To the 70 µl of cut lambda DNA 20 µl of  
20 10X universal buffer and 10 µl of the restriction enzyme Not I (8 U/µl, 80 U) are added. The  
solution is gently mixed by inversion and then incubated at 37°C for 2 h. Following the  
incubation, the solution is incubated at 68°C for 15 min.

5 The solution is then extracted twice with an equal volume of phenol followed by extraction once with an equal volume of chloroform. After the extractions, the cut human genomic DNA within the solution is precipitated by the addition of 2.5 volumes of ethanol and incubation at minus 20°C overnight or 20 min in a dry ice acetone bath. The pelleted, cut human genomic DNA is then resuspended in low TE buffer. The resuspended, cut human genomic DNA is then quantitated using a spectrophotometer, measuring absorbance at 260 nm and 280 nm. The digested Human genomic DNA is now ready for its role in the cloning into the vector.

#### Ligation of the Human Genomic DNA into the two lambda ZAP II arms.

10 A total of 1 µg of lambda vector arms at a ratio of 1 to 15, left arm to right arm, is mixed with 0.1 µg of the double cut human genomic DNA, 0.5 µl of 10X ligase buffer (500 mM Tris-HCl, pH 7.5, 70 mM MgCl<sub>2</sub>, 10 mM dithiothreitol), 1 mM rATP, and 0.5 µl of T<sub>4</sub> ligase (2 U; Stratagene) in a total volume of 5 µl. The solution is then incubated at 4°C overnight.

#### 15 Packaging of the human/lambda ZAP II library.

All procedures used for the packaging of the lambda/human DNA is described within the directions and package insert for the kit as provided by Stratagene.

#### Preparation of Host Bacteria

20 The bacterial glycerol stock contained within the kit is used to streak Luria-Bertani agar (LB, Bacto-tryptone 10 g/l, Bacto-yeast extract 5 g/L, NaCl 5 g/l and Bacto-agar 15 g/l). The bacterial glycerol stock contains the *Eschericia coli* strain VCS257. The streaked plates are incubated overnight at 37°C. A single colony is then used to inoculate LB media

supplemented with 10 mM MgSO<sub>4</sub> and 0.2% (w/v) maltose. The inoculated medium is incubated at 37°C with shaking for 4 - 6 h, not past an OD<sub>600</sub> of 1.0. After incubation, the cells are pelleted by centrifugation at 500-x g for 10 min. The cells are then gently resuspended in half their original volume in 10 mM MgSO<sub>4</sub>. The cells are now ready for use

5 in the packaging protocol.

#### Packaging Protocol

The packaging extracts provided with the kit are removed from the minus 80°C freezer and placed on dry ice. The tube is then quickly thawed by holding the tube between one's fingers. The human/lambda ZAP II DNA ligation mixture (1.7 µl) is added to the

10 packaging extract. The packaging mixture is then stirred with a pipette tip to insure even mixing. The tube is then quickly spun (3 - 5 seconds). The tube is then incubated at room temperature (22°C) for 2 hours. After the incubation 500 µl of SM buffer (100 mM NaCl, 8.11 mM MgSO<sub>4</sub>, 50 mM 1M Tris-HCl (pH 7.5), 0.01% gelatin) is added to the tube. Twenty µl of chloroform is then added to the tube and the contents are mixed. The tube is

15 spun briefly and the supernatant is transferred to a fresh tube. The phage contained within the supernatant are now ready for further usage.

These procedures have been carried out for four separated human genomes. The resulting four human/lambda libraries are being utilized for the detection of SNPs.

Example 2. Procedure by which the human/lambda phage library is utilized to detect

20 polymorphisms.

Following is a step by step description of the procedure for the discovery of SNPs within the human genome according to the invention.

#### Plating and picking of the human/lambda library

##### Plaque Plating

5           XL 2-Blue MRF' *Eschericia coli* cells are maintained as a stock by streaking the cells on LB agar for single colonies. Single colonies are used to inoculate 3 ml LB media. The bacteria are grown at 37°C for 6 hours with gentle shaking. After incubation, the bacteria are pelleted (500-x g) and then resuspended in 1.5 ml of 10 mM MgSO<sub>4</sub>. These cells are then used for transduction by the human/lambda library. Utilizing the appropriate library phage and the bacterial cells suspended in 10 mM MgSO<sub>4</sub>, plaque plates are generated as follows: 0.1 ml of the bacterial suspension is mixed with enough library phage to yield between 100 and 300 plaques per 150 mm agar plate. The mixture is incubated at room temperature for 5 min. After the incubation 2.5 ml of pre-warmed LB (37°C) is added followed by 2.5 ml of molten (45°C) top agar (10 g/l Bacto-tryptone, 5 g/l Bacto-yeast extract, 5 g/l NaCl and 7 g/l Bacto-agar). This mixture is then immediately poured over a pre-dried LB agar plate (pre-dried for 6 - 8 h at 37°C). Initially the plate is incubated right side up at room temperature. After 30 min the plate the plate is placed in a 37°C incubator bottom side down and incubated for a minimum of 10 h. Plaques begin to appear at 4 hrs. Plates are incubated for no longer than 8 hrs before they are removed from the incubator and placed at 4°C.

##### 20           Picking Plaques from the Plated Library

Plaques are picked by coring the middle of the plaque using a P200 pipetter and widebore P200 ART tips. Only the top agar is cored and used to make the plaque/phage

stocks. Once the plaque is cored, the agar plug is placed in 70 µl of SM buffer containing 5 µl of chloroform. Plaque/phage stocks are maintained in 96-well polystyrene plates.

Individual wells are capped and the plate is wrapped in Parafilm™ and stored at 4°C until they are used. Once a plate has been processed for additional procedures Dimethyl Sulfoxide (DMSO) is added to every well to final concentration of 10%. The plates are then stored at -80°C.

#### Plaque/phage Polymerase Chain Reaction

The inserted cloned human DNA is next amplified by PCR. Reactions are set up in 96-well formats that replicate the 96-well format of the plaque/phage stock plate. The PCR reactions are 25 µl in total volume and consist of the following 2 µl of plaque/phage stock, 2.5 U of Pfu Turbo, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dTTP, 0.1 mM dGTP, 0.1 mM 7-deaza dGTP, 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM Ammonium sulfate, 0.1% Triton X-100, 0.1 mg/ml BSA and 25 µM primers. The primers being utilized now for PCR are vector specific primers that allow amplification of both the inserted human DNA as well as fragments of the vector. Plaque/phage stocks are run in duplicate with the only difference being the addition of 5% DMSO to one of the duplicate wells. The PCR cycling conditions are as follows: 1 cycle of 98°C for 3 min; followed by 2 cycles 98°C for 2 min, 55°C for 50 sec, 75°C for 7 min followed by 29 cycles of 95°C for 50 sec, 58°C for 50 sec, 75°C for 7 min, followed by a final elongation at 75°C for 15 min.

Following PCR, the plus and minus DMSO plates are consolidated into one plate and stored at 4°C.

#### PCR Reaction Cleanup

5 PCR products are purified using a 96-well format by employing binding to glass fiber filters in a high salt solution. To each well an equal volume (approximately 50  $\mu$ l) of binding buffer (4 M guanidine isothiocyanate in 100 mM Tris-HCl (pH 6.4)) is added. The solution (binding buffer and PCR product) is then transferred to the appropriate well of the PCR purification plate. A vacuum is then applied to the PCR purification plate (400 mbar) until all of the liquid has been removed from the wells. The vacuum is then applied for an additional 5 min. After the 5 min. each well is washed with 750  $\mu$ l of wash buffer (75% ethanol, 2 mM Tris-HCl (pH 6.5), 10 mM NaCl). Vacuum is then again applied to the plate until the wells are dry. Vacuum is applied for an additional 15 min. The PCR purification plate is then centrifuged at 1000-x g for 10 min. The purified PCR product is eluted from the filter by the addition 50  $\mu$ l of 10 mM Tris-HCl (pH 8.5) to the filter, incubating at room temperature for 5 min, placing a 96-well collection plate underneath the PCR purification plate and centrifuging the plates at 1000 x g for 10 min.

#### Quantitation of the Purified PCR Product

15 In order to determine which PCR reactions have produced product and to quantitate the amount of purified PCR product present, the fluorescent dye picogreen is used. The procedure is as follows: in a 96-well plate 5  $\mu$ l of each purified PCR product is placed in the appropriate corresponding well which contains 95  $\mu$ l of TE. To each appropriate well 100  $\mu$ l of picogreen, which has been diluted 1 to 200 with TE, is added. The plate is then incubated in the dark for 10 min and then read with the proper spectrofluorometer at the appropriate wavelengths for excitation and emission. Utilizing the proper standards, wells that contain a PCR product can be consolidated into another 96-well plate.



## Sequencing of PCR Products

Consolidated, purified PCR products are then cycle-sequenced using BigDye Terminator chemistry (Perkin Elmer/Applied Biosystems). Other types of sequencing chemistries are also compatible with this process. Sequencing is done in a 384 well format and is carried out as follows: one or 2  $\mu\text{l}$  of the purified PCR product are mixed with 4  $\mu\text{l}$  of the BigDye Ready Reaction Mix, 1  $\mu\text{l}$  of the sequencing primer (either T7 or T3) and enough  $\text{dsH}_2\text{O}$  to bring the total reaction volume to 10  $\mu\text{l}$ . Cycle sequencing is then initiated using the following parameters: 25 cycles of 96°C for 25 sec, 45°C for 45 sec and 60°C for 4 min 25 sec. Samples are then precipitated by the addition of 2.5 volumes of 100% ethanol. The samples are incubated at room temperature for 15 min and then centrifuged at 3000 x g for 30 min. The plate is then inverted and placed on top of a paper towel and re-centrifuged at 400 x g for 1 min. The plates are then allowed to air dry for 15 min at room temperature. The pelleted cycle-sequencing product is then dissolved in 2.5  $\mu\text{l}$  80% formamide containing a tracking dye and 5 mM EDTA- $\text{Na}_2$ . Samples are denatured at 96°C for 2 min and then placed on ice before they are loaded onto the sequencing gel. Sequencing gels are set up and run according to standard procedures specified by the manufacturer Perkin Elmer/Applied Biosystems.

It should be noted that the process of SNP discovery is not limited to the procedures described above.

Example 3. Enriching for and Identifying a Nucleic Acid Sequence Difference With Respect to a Reference Sequence.

662290-5583360

In order to enrich a nucleic acid sample for a subset of nucleic acid molecules bearing a marker sequence, that sample is reacted with a sequence-specific binding activity under conditions that permit specific binding. The sequence specific binding activity can be any activity that binds to a particular sequence or sequence motif. Examples include, but are not limited to transcription factors or their DNA binding domains (e.g., Fos and Jun, see Cohen & Curran, 1990, Oncogene, 5: 929) proteins with zinc-finger DNA binding domains (Cohen et al., 1992, Science, 257: 1951), restriction endonuclease DNA recognition domains, sequence-specific antibodies (Erez-Alon et al., 1998, Cancer Res., 58: 5447), oligonucleotides complementary to an adapter ligated to a population of DNA molecules, nucleic acid molecules, aptamers (Hale & Schimmel, 1996, Proc. Natl. Acad. Sci. U.S.A., 93: 2755; Feigon et al, 1996, Chem. Biol., 3: 611), peptide nucleic acid molecules (Kuhn et al., 1999, J. Mol. Biol., 286: 1337; Ratilainen et al., 1998, Biochemistry, 37: 12331), peptides (Banks et al., 1999, J. Biol. Chem., 274: 16536) and affinity resins that recognize DNA having a particular G+C content or methylation status.

15        The binding conditions for the sequence specific binding activity used according to the invention are known by those skilled in the art. That is, the binding conditions will vary with the identity of the particular sequence-specific binding activity selected for use in the method of the invention, but in order for a particular sequence-specific binding activity to be selected for use in this method the conditions for its sequence-specific nucleic acid binding are known in the art.

20

For example, a DNA binding activity such as the NF- $\kappa$ B p50/p65 complex may be used to select molecules bearing NF- $\kappa$ B recognition sequences under binding conditions as

used for protein:nucleic acid binding in the well-known electrophoretic mobility shift assay (Kunsch et al., 1992, Mol. Cell. Biol., 12: 4412).

As another example, a nucleic acid may be used as a sequence-specific binding activity, according to the invention, under conditions known to those skilled in the art to permit specific hybridization or annealing to its complementary sequence. The nucleic acid used as a sequence specific binding activity according to the invention may be a double-stranded molecule having an overhang allowing annealing to molecules with a complementary overhang, or it may be a single-stranded oligonucleotide that hybridizes at a specific marker sequence on a sub-population of nucleic acids in the sample.

In cases where a double-stranded nucleic acid sequence with a specific overhang is used as a sequence-specific binding activity according to the invention, the interaction may be stabilized by the activity of a ligase, such as T4 DNA ligase, under conditions known in the art.

Conditions for hybridization or annealing of a single-stranded nucleic acid as a sequence-specific binding activity are similar to those used for annealing of primers in PCR applications. For example, standard PCR conditions call for annealing primers at a temperature 2°C to 5°C below the calculated  $T_m$  for a given primer in a buffer comprising 50 mM KCl, 10 mM Tris-HCl (pH 8.4) and 100 mg/ml gelatin (see Gelfand et al., supra). The annealing temperature for a given nucleic acid with its complement may be estimated according to the following formulae, which account for the length, G+C content, and salt conditions in the reaction. For oligonucleotides shorter than 14 bases, use the formula  $T_m = 2^{\circ}\text{C}(\text{A}+\text{T}) + 4^{\circ}\text{C}(\text{G}+\text{C})$ ; for oligonucleotides 14 bases and longer (up to 60-70 nucleotides),

use the formula  $T_m = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - (600/n)$ , where “n” is the chain length. For probes longer than 70 bases, use the formula  $T_m = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - (675/n)$ . Due to the effects of base stacking, near neighbor effect and buffering capacity, which will vary with the exact oligonucleotide sequence, these formulae give only a close approximation of  $T_m$ . However, it is well within the capacity of one of ordinary skill in the art to tailor temperatures to a particular oligonucleotide sequence, without undue experimentation, using these formulae as a starting point. Alternatively, a more precise  $T_m$  determination may be made using the method of Arnold et al., (U.S. Pat. No. 5,283,174).

10           The binding activity may be free in solution or attached to a solid support, such as beads or a nylon or nitrocellulose membrane to facilitate the physical separation of protein:nucleic acid complexes from unbound nucleic acids. One of skill in the art may attach binding activities such as proteins (including antibodies), peptides, nucleic acids, aptamers or peptide nucleic acids to solid supports for use with the method of the invention.

15           Attachment may be direct, as is possible for some activities on different types of solid supports (e.g., protein or nucleic acid binding to nitrocellulose or nylon membranes), or indirect, mediated for example by an antibody specific for the sequence specific binding activity or by a molecule, such as streptavidin, which recognizes a labeling moiety, such as biotin, on the sequence-specific binding activity.

20           As a specific example of the use of a sequence-specific binding activity to enrich for and identify a nucleic acid sequence difference with respect to a reference sequence, one may use the NF- $\kappa$ B p50 DNA binding protein to enrich for DNA molecules containing the

consensus sequence 5'-GGPuNNPyPyCC-3', and the enriched population may be analyzed for sequence differences. To do this, one must take the following steps:

1. Enrich a genomic DNA sample for molecules bearing the NF- $\kappa$ B consensus sequence.

DNA at least 20  $\mu$ g is incubated with beads bearing immobilized NF- $\kappa$ B p50 protein according to the binding conditions of Kunsch et al. (Kunsch et al., supra). The unbound DNA is removed by washing the beads three times with binding buffer, at ten times the packed volume of the beads per wash. Alternatively, the DNA-binding protein-bearing beads may be made into a column, with DNA being passed over the column in binding buffer. Unbound sequences are then removed by passing several void volumes of binding buffer without DNA over the column.

2. Detect a nucleic acid sequence difference with respect to a reference sequence.

The bound nucleic acid is eluted, using for example, 300 mM sodium acetate, pH 5.0. Under these conditions, the eluted DNA may be readily concentrated by ethanol precipitation. The DNA, thus enriched for molecules bearing the NF- $\kappa$ B consensus sequence is then ready for further enrichment or for analysis with respect to a reference sequence by any of the genotyping methods described elsewhere herein (e.g., DNA sequencing (including primer-guided microsequencing and minisequencing), exonuclease resistance, extension in solution using ddNTPs, GBA<sup>TM</sup>, ligase-polymerase GBA, OLA, dot-blot/allele-specific hybridization, SBH, denaturing HPLC, electrophoretic methods capable of distinguishing conformational differences between nucleic acids, or binding of proteins capable of detecting mismatches

between duplexed strands of nucleic acids . The enrichment protocol will increase the sensitivity and reduce the background in each of these methods.

#### Example 4. Enriching For and Identifying a Nucleic Acid Sequence Difference With Respect to a Reference Sequence.

5           In this example, the sequence specific cleavage agents NotI and EcoRI are used to select molecules bearing sequences near the infrequently occurring NotI sites in the genome. To do so, one will take the following steps:

1) Cleave a DNA sample with NotI and EcoRI. The DNA may be genomic or, for example, cDNA made by reverse-transcription of a total RNA or mRNA sample. Cleavage is  
10 performed according to the conditions specified by the supplier of the enzymes.

2) Ligate the sub-population of molecules having both a NotI- and an EcoRI-cleaved end to molecules facilitating their replication. The molecules facilitating replication of the linked DNA may be either an appropriate plasmid cleaved with both NotI and EcoRI (for example, pBluescript II SK, Stratagene), or they may be double-stranded oligonucleotides  
15 with overhangs allowing annealing and ligation to the NotI and EcoRI ends of the cleaved DNA. Such oligonucleotides may be free in solution or they may be immobilized on a solid support.

Alternate replication vectors may also be used, such as bacteriophage lambda DNA. For example, Lambda ZAP (Stratagene) is digested with Not I and EcoR I and ligated with  
20 the DNA sample. There are several techniques that can be used to enrich for vector containing only fragments with Not I and EcoR I ends. For example, the sample DNA may

be cleaved with EcoR I first, then treated with an alkaline phosphatase, such as calf intestinal alkaline phosphatase (Boehringer Mannheim) according to the manufacturer's instructions, to remove 5' phosphates from the sample DNA, then digested with Not I. The Not I/EcoR I digested fragments will be able to ligate with the vector DNA, but EcoR I/EcoR I sample DNA fragments will not be able to ligate with each other, thus reducing the frequency of inserts containing EcoR I/EcoR I fragments.

Another method is to use excess vector having an EcoR I compatible end. For example, Lambda ZAP DNA may be cleaved with Not I and Hind III. Such double digestion leaves a replication-competent left arm of lambda, but cleaves the right arm into multiple fragments. Another preparation of Lambda ZAP DNA may be cleaved with EcoR I and Mlu I. Such double digestion leaves a replication-competent right arm of lambda, but cleaves the left arm into multiple fragments. Since Mlu I cleaves lambda many times in the left arm, and Hind III cleaves lambda many times in the right arm, such double-digested preparations do not efficiently produce replication-competent lambda genomes upon exposure to T4 DNA ligase. Moreover, if both double-digested preparations are mixed together and exposed to T4 DNA ligase, replication-competent lambda genomes are still rare. However if such double-digested preparations are mixed together along with sample DNA that has been digested with Not I and EcoR I, then DNA fragments that have been cleaved at one end by Not I and at the other end by EcoR I will be able to ligate with the functional Not I-cleaved left arm from one lambda preparation and ligate with the functional EcoR I-cleaved right arm from the other lambda preparation to produce replication-competent lambda genomes with reasonably high efficiency. This is provided that the Not I/EcoR I cleaved sample DNA fragments are of

appropriate size for lambda replication, which for Lambda ZAP would be fragments up to about 9 kilobases in length. If a fragment with Not I cleavages at both ends, or a fragment with EcoR I cleavages at both ends ligates with one of the lambda arms, it would not be able to ligate with the opposite lambda arm, and thus would form a replication-incompetent product. Since EcoR I cleaves human DNA about 25 times more frequently than does Not I, one can add about 25 times more lambda right arms, as compared with left arms (molar ratio), to the ligation reaction. This will increase the probability that each Not I/EcoR I-cleaved sample fragment will ligate with an EcoR I-cleaved right arm rather than another EcoR I-cleaved sample DNA fragment. Such unwanted ligation of EcoR I-cleaved sample fragments can also be reduced by treatment with an alkaline phosphatase, such as calf intestinal alkaline phosphatase.

Another method to enrich for ligated molecules containing only Not I/EcoR I doubly cleaved sample fragments, is to cleave the sample DNA first with Not I, then ligate the cleaved DNA with a plasmid vector that comprises a Not I and an EcoR I site, but has been cleaved only with Not I. After ligation, the DNA is cleaved with EcoR I, which cleaves both the vector DNA and the sample DNA. Following inactivation of the EcoRI activity, the sample is diluted and ligated using T4 DNA ligase. Diluted DNA preferentially circularizes as opposed to forming bimolecular reactions. Thus there will be a large fraction of circularized plasmids containing Not I/EcoR I cleaved sample DNA.

3) Replicate the linked molecules generated in step 2.



When the molecules facilitating replication of the linked DNA comprise a plasmid, this comprises the steps of transforming competent host cells (Stratagene) and selecting for transformants according to standard methods.

When the molecules facilitating replication of the linked DNA comprise a lambda  
5 genome, this comprises the steps of transfecting host cells and selecting for growth of lambda bacteriophage according to standard methods. Lambda bacteriophage packaging extract (Gigapack™, Stratagene) can be used to greatly increase the efficiency of lambda DNA transfection.

When the molecules facilitating replication of the linked DNA are oligonucleotides or  
10 adapters, this comprises the annealing of a primer complementary to one strand of the oligonucleotides or adapters ligated to the NotI cleaved or NotI/EcoRI cleaved DNA fragments and polymerizing the complementary strand of the ligated molecule with a template-dependent DNA polymerizing enzyme (e.g., Klenow DNA polymerase or Taq DNA polymerase; conditions for primer extension with these enzymes and others are well known  
15 in the art). Examples of such replication can be found in Lisitsyn et al., 1993, Science, 259: 946; Hubank & Schatz, 1994, Nucl. Acids Res., 22: 5640; Hou et al., 1996, Nucl. Acids Res., 24: 2196; Suzuki, et al., 1996, Nucl. Acids Res., 24: 797; and Lukyanov et al., 1996, Nucl. Acids Res., 24: 2194. In order to enrich for those sequences near NotI sites, one uses a primer complementary to the adapter ligated to the NotI ends of the cleaved population. The  
20 degree of enrichment may be enhanced by repeating the polymerization reaction. In this regard, thermostable polymerases such as Taq DNA polymerase have the advantage of permitting cycles of annealing and extension, which increases the degree of enrichment with

each cycle. Alternatively, strand displacing polymerases can be used to produce multiple copies of the linked DNAs at a single temperature (US patent 5,744,311).

Alternatively, if a double-stranded oligonucleotide ligated to one end of the cleaved molecules generated in step (1) comprises a transcriptional promoter, such as the  
5 bacteriophage T7 promoter, the replication step may comprise the steps of adding RNA polymerase (e.g., T7 polymerase) and ribonucleotides under conditions allowing RNA polymerization from the ligated promoter. Conditions for such in vitro transcription are well known in the art (US patents 5,891,636 and 5,716,785), and the transcripts may be labeled if  
10 necessary (labels include, but are not limited to a fluorescent molecule, radioactive molecule, hapten, or biotin). Under optimal conditions, up to 700 moles of transcript can be generated per mole of DNA template, thereby giving as much as a 700-fold enrichment for sequences bearing a ligated promoter.

4) Detect one or more nucleic acid sequence differences with respect to a reference sequence in the replicated population of molecules.

15 Detection of nucleic acid sequence differences in the enriched sub-population generated in step (3) is then achieved using any of the genotyping methods described herein. These methods include, for example, DNA sequencing (including primer-guided microsequencing and minisequencing), exonuclease resistance, extension in solution using ddNTPs, GBA<sup>TM</sup>, ligase-polymerase GBA, OLA, dot-blot/allele-specific hybridization, SBH,  
20 denaturing HPLC, electrophoretic methods capable of distinguishing conformational differences between nucleic acids, or binding of proteins capable of detecting mismatches

between duplexed strands of nucleic acids . The enrichment protocol will increase the sensitivity and reduce the background in each of these methods.

When the in vitro replication system involves transcription from a ligated bacterial promoter, allele-specific (dot-blot) hybridization may be used to detect sequence differences.

- 5 Alternatively, the ribonuclease protection assay may be used to detect sequence differences in RNA molecules. The method of RNase protection is well known in the art, and several companies sell kits for the method, including Ambion (RPAII™ kit, Cat. # AM-1410) and Pharmingen (RiboQuant™ kit). The method involves synthesis of an RNA probe from a plasmid bearing a bacteriophage promoter and an insert containing the reference sequence.
- 10 The RNA probe is then hybridized with the RNA generated in the enrichment protocol. A ribonuclease capable of cleaving single stranded or mismatched duplexes, but not perfectly matched duplexes, is then added. Cleaved duplexes provide evidence of mutations in the sample RNA as compared with the reference RNA. Typically these cleavage products are identified by gelelectrophoresis.
- 15 Alternatively, the RNA can be sequenced directly using Sanger sequencing and the enzyme reverse-transcriptase. The RNA may also be converted to cDNA, and then the cDNA may be sequenced.

Example 5. Enriching For and Identifying a Nucleic Acid Sequence Difference With Respect to a Reference Sequence.

In this example, the sequence specific cleavage agents NotI and EcoRI are used to select molecules bearing sequences near the infrequently occurring NotI sites in the genome. To do so, one will take the following steps:

1) Cleave a DNA sample with NotI and EcoRI.

5           The DNA may be genomic or, for example, cDNA made by reverse-transcription of a total RNA or mRNA sample. Cleavage is performed according to the conditions specified by the supplier of the enzymes or as known in the art.

2) Link the sub-population of molecules having a NotI end to molecules facilitating their separation.

10           A useful reference for this procedure is Hultman & Uhlen, 1994, J Biotechnol, 30:35:229. The molecules facilitating separation of the molecules with NotI ends may be double-stranded oligonucleotides with NotI-compatible overhangs allowing annealing of the cleaved DNA. The annealed NotI fragments are then ligated to the double-stranded oligonucleotides with ligase under standard conditions. This process will link those sequences near NotI sites  
15   to molecules facilitating their separation from those sequences further than the nearest EcoRI recognition sequence from a NotI recognition sequence.

3. Separate the linked molecules.

          The oligonucleotides may be bound to a solid support at any point before, during or after annealing and ligation of the DNA fragments. In any case, the fragments linked to the  
20   oligonucleotides are separated from those not linked to the oligonucleotides by washing the

solid support after linkage of the oligonucleotides to the population of fragments. Wash buffer may be a standard buffer such as TE (10 mM Tris pH 8.0, 1 mM EDTA), or any buffer compatible with the solid support and method of oligonucleotide linkage to it.

4. Detect one or more sequence differences in the bound population with respect to a
- 5 reference sequence.

Methods of detecting sequence differences appropriate for this enriched population include DNA sequencing, denaturing HPLC, electrophoresis capable of differentiating conformational differences in nucleic acids, and binding to a protein capable of detecting mismatches between duplexed strands of nucleic acid.

- 10 Example 6. Enriching For and Identifying Nucleic Acid Sequence Differences With Respect to a Reference Sequence.

- In this example, a sample of nucleic acid is treated to generate fragments that are then bound to a sequence-specific binding activity to effect an enrichment for either those molecules bearing or lacking the sequence bound by that activity. To do so, one must
- 15 perform the following steps.

- 1) Fragment a nucleic acid sample to the chosen approximate average fragment length.

- A nucleic acid sample may be fragmented to facilitate the enrichment for molecules bearing a particular marker sequence. Fragmenting may be accomplished by physical means, such as shearing, or by cleavage with an agent such as a restriction endonuclease. While
- 20 other cleavage agents are useful according to the invention, restriction endonucleases are particularly useful for several reasons. First, the frequency of cutting for a particular

restriction endonuclease, and thereby the average fragment length generated by digestion of a genomic or other DNA sample, is often known or predictable based on the length of the recognition sequence and the nucleotide makeup of the recognition sequence (G/C or A/T-rich, for example). Similarly, the average fragment length for a combination of two or more restriction endonucleases may be predicted. Therefore, DNA may be fragmented to a selected average fragment length by selection of two or more restriction endonucleases of the appropriate known cutting frequencies. It should be noted that there are cases in which a restriction endonuclease will not generate fragments of a size predicted on the basis of the base composition of its recognition sequence. For example, if a recognition sequence for a particular enzyme occurs in a highly repeated segment of DNA, the average number and size of the fragments will be altered relative to a similar sequence not occurring in a repeated element. In practice, the average size of fragments generated by a given restriction endonuclease may be estimated by examination of fragments after electrophoretic separation on a gel. For additional information on the distribution and size fractionation of restricted genomic DNA fragments, see Gondo, 1995, Electrophoresis, 16: 168.

Another advantage of fragmenting with restriction endonucleases is that many of the known enzymes cleave so as to generate an overhang on one strand. That overhang may be exploited in subsequent steps. For example, the portion of the cleaved population bound to a sequence specific binding activity may be ligated or annealed to a nucleic acid molecule that permits its cloning to form a library of sequences. Alternatively, the cleaved, bound population may be ligated or annealed to a primer that permits its replication or transcription. The replication or transcription of the molecules bound to the sequence-specific binding

activity will further enrich the population and facilitate the detection of sequence differences in the bound subset of nucleic acid molecules with respect to a reference sequence.

2) Physically separate a subset of the nucleic acid fragments generated in step (1) based on the presence or absence of a particular nucleic acid sequence.

5           Fragments bearing a given sequence or sequence motif may be separated from those lacking such a sequence with a sequence-specific binding activity under conditions compatible with sequence-specific binding by that activity (see, for example, Example 3). It should be understood that either the population bearing or the population lacking the particular sequence or sequence motif bound by a sequence-specific binding activity, or both,  
10   may be further analyzed as enriched populations.

3) Link the subset of nucleic acid molecules physically separated in step (2) to molecules facilitating the replication of the subset.

When the cleavage method used is random, such as, for example, physical shearing, a method such as that taught by Andersson et al. can be used to link the subset of molecules to  
15   molecules facilitating their replication (Andersson et al., 1996, Anal. Biochem., 236: 107). Briefly, the method involves enzymatic repair (blunting) of the ends of the sheared molecules, followed by ligation to adapters with 12bp overhangs. The oligonucleotide adapters used are non-phosphorylated, thus preventing formation of adapter dimers and ensuring efficient ligation of fragments to the adapters. The ligated fragments are then  
20   annealed to a modified M13 vector with ends complementary to the adapter overhangs and transformed into bacteria without ligation.

4) Replicate the subset of molecules linked in step (3).

Linked molecules may be replicated as in Example 4, section 3.

5) Detect a sequence difference with respect to a reference sequence.

Detection of sequence differences with respect to a reference sequence may be performed using the same methods indicated in Example 4, section 4, above, or any suitable method known in the art.

Example 7. Enriching For and Identifying Nucleic Acid Sequence Differences With Respect to a Reference Sequence.

In this example, the sequence specific binding activity is one or more oligonucleotide primers that hybridize to a sequence that occurs at least twice, but can occur for example 3, 4, 5, 10, 20, 50, 100, 1000, 10,000, 25,000, 50,000 or even 100,000 times or more per genome (see AP-PCR, Welsh & McClelland, 1990, supra; and RAPD, Williams et al., 1990, supra). To enrich for and identify nucleic acid sequence differences with respect to a reference sequence according to this method, one must perform the following steps.

1) Hybridize a nucleic acid sample from one or more individuals with oligonucleotide primers.

Conditions for annealing primers, particularly as used in PCR applications, are well known in the art (Gelfand et al., supra). A primer for this particular method may be as short as about five to eight nucleotides, although longer primers are permissible or even preferred



in some situations (see below). The number of extension products is a function of the efficiency of annealing under a given set of conditions, and can be manipulated by one of skill in the art to give a desired approximate number of extension products. For example, in general, the annealing temperature is inversely proportional to the number of extension products for a given primer on nucleic acid from a given species. Therefore, the higher the annealing temperature, the fewer the productive extension events. Other factors, such as the makeup of the polymerization buffer or the presence of chain-terminating nucleoside analogs can also be varied to change the makeup of the extended population (see below).

- 2) Extend the annealed oligonucleotide primers to form an enriched collection of replicated molecules.

Extension may be performed with a template-dependent DNA polymerase such as Taq DNA polymerase or Klenow DNA polymerase. Alternatively, extension of an oligonucleotide annealed to an RNA template may be extended with reverse transcriptase.

- Annealing and extension may be repeated to increase the degree of enrichment with any of the enzymatic systems described. As noted, however, Taq DNA polymerase has the advantage of allowing multiple cycles of annealing and extension without requiring repeated enzyme addition. It is also noted that the processivity of Taq DNA polymerase is sensitive to the concentration of  $Mg^{+2}$  in the reaction, and can be varied by one skilled in the art to vary the characteristics of the extended products.

- Under some circumstances (e.g., when one wishes to further limit the complexity of the resulting population, or when one wishes to generate an incomplete extension product),

one may add a chain-terminating nucleoside analog to the extension mixture at a concentration that limits the length of the average extension product. Within this embodiment of the invention, one may wish to limit the length of the average extension product to any length between about 500 and 5000 nt. One of skill in the art may determine  
5 the concentration of chain-terminating nucleoside analog to add to achieve a given desired average extension product length with a minimum of experimentation.

The extension products may be detectably labeled either by labeling the primer, or by incorporation of labeled nucleotides by the polymerase. Labels of use according to this embodiment of the invention include, but are not limited to fluorescent moieties, radioactive  
10 moieties, biotin, and digoxigenin.

Enrichment may also be enhanced by annealing and extending a primer complementary to the original extended primer and repeating the extension steps. The oligonucleotide primer may also have an additional 3'-terminal extension immediately adjacent to the sequence complementary to the selected sequence. This extension, which  
15 may be one, two, three, on up to eight nucleotides or more beyond the sequence complementary to the selected sequence, will effect further reduction in the complexity of the population when the primers are extended in the following steps.

### 3) Detect a sequence difference with respect to a reference sequence.

Detection of sequence differences may be accomplished using any of the methods  
20 described in Examples 3 or 4, or elsewhere herein, or as known in the art.

Example 8. Enriching For and Detecting a Nucleic Acid Sequence Difference With Respect to a Reference Sequence.

In this example, a nucleic acid sample is fragmented and a subset of fragments is physically separated on the basis of their size. To perform the method, one must perform the following steps.

1) Fragment a nucleic acid sample from one or more individuals.

Nucleic acids may be fragmented by any of the methods discussed above.

2) Physically separate a subset of the fragments based on their size.

Physical separation of nucleic acid fragments by size may be accomplished in several different ways. First, electrophoretic separation on a gel matrix may be performed according to standard methods using agarose or polyacrylamide gel electrophoresis (see Ausubel et al., supra, pp. 2-13 and 2-23).

Second, fragments may be separated based on their position in a density gradient. CsCl density gradient ultracentrifugation of nucleic acids is a standard method well known in the art. Also, the rate of migration of DNA in a high-density sucrose gradient will vary with the size of the fragment (see, for example, Schans et al, 1969, Anal. Biochem., 32: 14). This is not a function of the density of the DNA, but of the size of the DNA and the effects of viscosity on migration. One may establish a gradient by centrifugation, remove fractions with a fraction collector, and purify nucleic acids of a desired size (evaluated by electrophoresis of a sample from a fraction alongside nucleic acid standard markers).

3) Optionally linking the subset of fragments isolated on the basis of their size to molecules facilitating the replication of the linked subset.

Linkage may be performed by annealing and/or ligation of the subset of molecules isolated in step (2) to either a plasmid or to an oligonucleotide as described above in Example 4, section 2.

4) Replicate the subset of fragments linked in step (3) to form an enriched collection of replicated molecules.

Replication may be performed in the same manner as replication of the subset of nucleic acid molecules performed in Example 3.

5) Detect one or more sequence differences in the members of the enriched collection generated in step (4) with respect to a reference sequence.

Detection of sequence differences is performed according to the same methods as described for Example 8.

#### Example 9. Accessing a Sub-Portion of a Nucleic Acid Population.

In this example, oligonucleotide primers are used to access a sub-portion of a nucleic acid population in order to reduce the complexity of the population and facilitate subsequent analysis (e.g., identification of polymorphisms). An advantage of this method is that it allows reproducible access to a given sub-portion of nucleic acid molecules from the same individual and from different individuals within a given population. To access a sub-portion

of a nucleic acid population according to this aspect of the invention, one must perform the following steps.

1. Anneal one or more oligonucleotide primers with a sample of nucleic acid.

The oligonucleotide primers used comprise a 3'-terminal sequence complementary to  
5 a selected sequence present in the nucleic acid molecules of the sample. The length of the  
sequence may be varied depending on the size of the sub-portion of the sequences one wishes  
to access, but will generally be at least about 5 nt in length or longer. The sequence may  
correspond to any sequence known or predicted to occur in the molecules of the nucleic acid  
sample. In addition to the sequence complementary to a selected sequence, the  
10 oligonucleotide primer may have additional nucleotides 5' of the selected sequence that will  
facilitate subsequent analysis steps.

The oligonucleotide primer may also have an additional 3'-terminal extension  
immediately adjacent to the sequence complementary to the selected sequence. This  
extension, which may be one, two, three, on up to eight nucleotides or more beyond the  
15 sequence complementary to the selected sequence, will effect further reduction in the  
complexity of the population when the primers are extended in the following steps.

According to this embodiment of the invention, the oligonucleotide primers may  
additionally be attached to a solid support or be labeled with a moiety allowing attachment to  
a solid support. Methods for attaching oligonucleotides to solid supports are known in the  
20 art.

One skilled in the art may determine the annealing conditions for a given oligonucleotide primer or primers in this method (see Example 3). The conditions for annealing will depend on the length and G+C content of the hybrid comprising the selected sequence and its complement in the oligonucleotide primer, plus any 3' terminal extension, and on the salt concentration of the buffer used. Generally, the salt concentration will correspond to the optimal concentration for the template-dependent polymerase chosen for the primer extension step.

2) Extend the annealed primer to generate a population comprising a sub-portion of the nucleic acid molecules in the sample.

Extension of the annealed oligonucleotide primers is performed using a template-dependent polymerase such as Taq DNA polymerase or Klenow DNA polymerase under conditions either as specified by the enzyme supplier or as modified by one of skill in the art. Under certain circumstances (e.g., when one wishes to further limit the complexity of the resulting population), one may add a chain-terminating nucleoside analog to the extension mixture at a concentration that limits the length of the average extension product. Within this embodiment of the invention, one may wish to limit the length of the average extension product to any length between about 500 and 5000 nt. One of skill in the art may determine the concentration of chain-terminating nucleoside analog to add to achieve a given desired average extension product length with a minimum of experimentation.

The extension products may be detectably labeled either by labeling the primer, or by incorporation of labeled nucleotides by the polymerase. Labels of use according to this

embodiment of the invention include, but are not limited to fluorescent moieties, radioactive moieties, biotin, and digoxigenin.

The sub-portion of the nucleic acid population accessed according to this embodiment of the invention represent a population of reduced complexity that may then be used to  
5 identify a nucleic acid sequence polymorphism in a population or in an individual using methods as described elsewhere herein.

#### Example 10. Accessing a Sub-Population of a Genome.

In this example, a sub-population of a genome is accessed in order to reduce the complexity of the genome for subsequent analyses. According to this aspect of the invention,  
10 one must take the following steps.

1) Cleave a nucleic acid sample with one or more cleavage agents.

The cleavage agent or agents may be sequence-specific cleavage agents, and will preferably cleave infrequently in the genome. Cleavage with a sequence-specific cleavage agent may be performed as described in Example 4, as described elsewhere herein, or in a  
15 manner known in the art for a given cleavage agent.

2) Link an oligonucleotide to the ends generated by the sequence-specific cleavage agent.

Linkage may be by annealing, or by ligation or both. In the case where linkage is by annealing, this step involves addition of either single-stranded oligonucleotides or double-stranded oligonucleotides with a single-stranded overhang capable of annealing to the ends

generated by the cleavage agent. It is possible to achieve extension of an oligonucleotide annealed but not ligated to a fragment by way of an overhang.

When an oligonucleotide is ligated, it will be a double-stranded oligonucleotide adapter with an overhang capable of annealing to the fragment ends generated by the

5 cleavage agent. In some instances the annealed oligonucleotide may regenerate the sequence recognized by the sequence-specific cleavage agent. It is also possible to ligate an oligonucleotide adapter comprising a free end or nick capable of being extended by a strand-displacing polymerizing activity. It is also possible to ligate an adapter comprising a sequence capable of being nicked (e.g., an adapter with a mismatched bulge susceptible to

10 cleavage by an enzyme, such as S1 nuclease, that cleaves at mismatched bases).

3) Extend the oligonucleotide linked in step (2).

Extension may be achieved, as noted in step (2) by addition of a nucleic acid polymerizing activity and nucleotides under conditions favored for the particular polymerizing activity used.

15 Alternatively, extension may be achieved by annealing a single-stranded oligonucleotide complementary to an oligonucleotide ligated in step (2), or complementary to the sequence-specific cleavage agent site regenerated by the ligated sequence, and adding a nucleic acid polymerizing activity and nucleotides under conditions favored for the particular polymerizing activity used. Nucleic acid polymerizing activities may include any template-

20 dependent polymerizing activity, such as, without limitation, Klenow DNA polymerase, Taq



DNA polymerase, or an RNA polymerase such as Sp6, T7 or T3 RNA polymerase. In the case of RNA polymerases, the oligonucleotide ligated to the cleaved fragments must comprise a promoter sequence for the selected RNA polymerase.

The extension may be repeated to increase the enrichment of sequences.

5 In order to generate an enriched sub-portion of the genome by this method, the extension must be limited to avoid the theoretical replication of the entire genome, which would not enrich for sequences near the sites recognized by the sequence-specific cleavage agent. One way to limit the length of the extension products is to include a chosen concentration of chain-terminating nucleotide analogs (such as dideoxynucleotides) to the  
10 extension mix. For example, one may add enough of a dideoxynucleotide to limit the average extension product to about 500 nt, 750 nt, 1000 nt, 1500 nt, 2000 nt, 3000 nt, 4000 nt, or even about 5000 nt. For a sequence-specific cleavage agent that gives an average fragment size of 10,000 base pairs or more, this will result in replication of less than half the sequence of the average fragment. That is, the inclusion of one or more chain terminating  
15 nucleotide analogs will result in the generation of an incomplete extension product.

Another aspect of this method that will further reduce the complexity of the nucleic acid molecule population is the use of a primer that has a 3'-terminal extension immediately adjacent to the cleavage agent recognition site. This extension, which may be one, two, three, on up to eight nucleotides or more beyond the sequence complementary to the sequence  
20 recognized by the cleavage agent, will effect a further reduction in the complexity of the population when the primers are extended. The reduction in complexity effected by the



[illegible]

a) contacting a nucleic acid sample with a molecule comprising a sequence-specific binding activity under conditions which permit specific binding, wherein said sample

10           b) detecting a sequence difference with respect to a reference sequence in the subset  
of nucleic acid molecules.

95

3. The method of either of claims 1 or 2 wherein said sequence-specific binding activity is bound to a solid support.

4. A method of identifying nucleic acid sequence differences with respect to a reference sequence comprising:

5 a) cleaving a nucleic acid sample from one or more individuals with one or more sequence-specific cleavage agents to produce nucleic acid fragments;

b) operatively linking said fragments with molecules capable of being replicated;

c) introducing the linked molecules of step (b) into a system capable of replicating only a subset of said linked molecules, and replicating said subset to form a collection of  
10 replicated molecules; and

d) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of said collection of step (c) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

5. The method of claim 4 wherein said system capable of replicating said linked  
15 molecules comprises host cells and the collection of replicated molecules comprises a library.

6. The method of claim 4 wherein said method capable of detecting one or more nucleotide differences comprises DNA sequencing.

7. The method of claim 4 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

8. The method of claim 4 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

9. The method of claim 4 wherein said method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

10. The method of claim 6 wherein said sequencing is performed using primers that hybridize to the molecules capable of being replicated.

11. The method of claim 4 wherein said system capable of replicating said linked molecules comprises in vitro replication of said linked molecules.

12. The method of claim 11 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to said molecules capable of being replicated.

13. The method of claim 11 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising both a segment of said molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to said molecules capable of being replicated.

5 14. The method of claim 4 wherein said cleavage agents are restriction endonucleases.

15. The method of claim 14 wherein at least one restriction endonuclease cleaves DNA infrequently.

16. The method of claim 15 wherein the infrequently cleaving restriction endonuclease is selected from the group consisting of AscI, BssHII, EagI, NheI, NotI, PacI, PmeI, RsrII, Sall, 10 SbfI, SfiI, SgrAI, SpeI, SrfI, and SwaI restriction endonucleases.

17. A method of identifying nucleic acid sequence differences with respect to a reference sequence comprising:

- a) cleaving a nucleic acid sample from one or more individuals with one or more sequence-specific cleavage agents to produce nucleic acid fragments;
- 15 b) operatively linking said subset of step (a) with said separation element;
- c) separating said linked molecules; and

d) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of said separated molecules of step (c) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

18. The method of claim 17 wherein said method capable of detecting one or more  
5 nucleotide differences comprises DNA sequencing.

19. The method of claim 17 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

20. The method of claim 17 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational  
10 differences in the nucleic acids.

21. The method of claim 17 wherein said method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

22. The method of claim 18 wherein said sequencing is performed using primers that  
15 hybridize to the sequences capable of being operatively linked to a separation element.

23. The method of claim 17 wherein said cleavage agents are restriction endonucleases.

24. The method of claim 23 wherein at least one restriction endonuclease cleaves DNA infrequently.

25. The method of claim 24 wherein the infrequently cleaving restriction endonuclease is selected from the group consisting of AscI, BssHII, EagI, NheI, NotI, PacI, PmeI, RsrII, Sall, 5 SbfI, SfiI, SgrAI, SpeI, SrfI, and SwaI restriction endonucleases.

26. A method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising:

a) fragmenting a nucleic acid sample from one or more individuals to an average fragment length;

10 b) physically separating a subset of the nucleic acid fragments generated in step (a) based on the presence or absence of a particular nucleotide sequence within said fragments;

c) operatively linking said subset of step (b) with molecules capable of being replicated;

15 d) introducing the linked molecules of step (c) into a system capable of replicating said linked molecules, and replicating said linked molecules to form a collection of replicated molecules; and

e) detecting a nucleic acid sequence difference with respect to a reference sequence in the collection of replicated molecules of step (d) using a method capable of detecting one or more nucleotide differences with respect to a reference sequence.



27. The method of claim 26 wherein said system capable of replicating said linked molecules comprises host cells and said collection of replicated molecules comprises a library.

28. The method of claim 26 wherein said method capable of detecting one or more  
5 nucleotide differences comprises DNA sequencing.

29. The method of claim 26 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

30. The method of claim 26 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational  
10 differences in the nucleic acids.

31. The method of claim 26 wherein said method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

32. The method of claim 28 wherein said DNA sequencing is performed using primers  
15 that hybridize to the molecules capable of being replicated.

33. The method of claim 26 wherein said system capable of replicating said linked molecules comprises in vitro replication of said linked molecules.

34. The method of claim 33 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to said molecules capable  
5 of being replicated.

35. The method of claim 33 wherein said in vitro replication is repeated one or more times to increase the enrichment of said linked molecules.

36. The method of claim 33 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising  
10 both a  
segment of said molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to said molecules capable of being replicated.

37. The method of claim 26 wherein the method used to physically separate a subset of fragments comprises using a sequence-specific binding molecule.

15 38. The method of claim 37 wherein the sequence-specific binding molecules is a protein.

39. The method of claim 26 wherein said fragmenting is performed using one or more sequence-specific cleavage agents.

40. The method of claim 39 wherein said sequence-specific cleavage agents are restriction endonucleases.

5 41. A method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising:

a) fragmenting a nucleic acid sample from one or more individuals to an average fragment length;

10 b) separating a subset of the nucleic acid fragments based on the presence or absence of a nucleotide sequence within said fragments;

c) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of said separated molecules of step (b) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

42. The method of claim 41 wherein said method capable of detecting one or more  
15 nucleotide differences comprises DNA sequencing.

43. The method of claim 41 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

44. The method of claim 41 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

45. The method of claim 41 wherein said method capable of detecting one or more  
5 nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

46. The method of claim 42 wherein said DNA sequencing is performed using primers that hybridize to the molecules capable of being replicated.

47. The method of claim 41 wherein the method used to physically separate a subset of  
10 fragments comprises using a sequence-specific binding molecule.

48. The method of claim 47 wherein the sequence-specific binding molecule is a protein.

49. A method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising:

a) hybridizing a nucleic acid sample from one or more individuals with  
15 oligonucleotide primers under conditions wherein each of said primers permits extension by a polymerase at two or more different sequences, and wherein the sequences replicated by

extension of said primers comprise regions where there are known sequence differences between individuals of the species being examined;

b) extending said oligonucleotide primers hybridized in step (a) to form an enriched collection of replicated molecules; and

5 c) detecting one or more nucleic acid sequence differences in the members of said collection with respect to a reference sequence with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

50. The method of claim 49 wherein said method capable of detecting one or more nucleotide differences comprises DNA sequencing.

10 51. The method of claim 49 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

52. The method of claim 49 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational differences in the nucleic acids.

15 53. The method of claim 49 wherein said method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

54. The method of claim 50 wherein said DNA sequencing is performed using primers that hybridize to the primers hybridized in step (a) and extended in step (b).

55. The method of claim 49 wherein steps (a)-(b) are repeated one or more times to increase the enrichment of said enriched collection of replicated molecules.

5 56. The method of claim 49 wherein said method further comprises, after step (b) and before step (c) the step of hybridizing a second set of primers that hybridize specifically to sequences comprising both a segment of said first set of primers and a segment of the replicated portion of the molecules generated in step (b).

57. A method of enriching for and identifying nucleic acid sequence differences with  
10 respect to a reference sequence comprising:  
a) fragmenting a nucleic acid sample from one or more individuals;  
b) physically separating a subset of said nucleic acid fragments based on the size of the fragments.

c) operatively linking said subset of step (b) with molecules capable of being  
15 replicated;

d) introducing the linked subset of molecules of step (c) into a system capable of replicating said linked subset of molecules, and replicating said subset of linked molecules to form an enriched collection of replicated molecules; and



63. The method of claim 59 wherein said sequencing is performed using primers that hybridize to the molecules capable of being replicated.

64. The method of claim 57 wherein said system capable of replicating said linked molecules comprises in vitro replication of said linked molecules.

5 65. The method of claim 64 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to said molecules capable of being replicated.

66. The method of claim 64 wherein said in vitro replication is repeated one or more times to increase the enrichment of said collection of replicated molecules.

10 67. The method of claim 64 wherein said in vitro replication comprises a step utilizing primers for nucleic acid polymerization that hybridize specifically to sequences comprising both a segment of said molecules capable of being replicated and the fragment ends of a subset of the nucleic acid molecules linked to said molecules capable of being replicated.

68. The method of claim 57 wherein the physical separation by size of step (b) is  
15 accomplished using electrophoresis or density gradient centrifugation.



69. A method of enriching for and identifying nucleic acid sequence differences with respect to a reference sequence comprising:

- a) fragmenting a nucleic acid sample from one or more individuals;
- b) physically separating a subset of said nucleic acid fragments based on the size of  
5 the fragments;
- c) detecting one or more nucleic acid sequence differences with respect to a reference sequence in the members of said separated molecules of step (b) with a method capable of detecting one or more nucleotide differences with respect to a reference sequence.

70. The method of claim 69 wherein said method capable of detecting one or more  
10 nucleotide differences comprises DNA sequencing.

71. The method of claim 69 wherein said method capable of detecting one or more nucleotide differences comprises denaturing HPLC.

72. The method of claim 69 wherein said method capable of detecting one or more nucleotide differences comprises electrophoresis capable of detecting conformational  
15 differences in the nucleic acids.

73. The method of claim 69 wherein said method capable of detecting one or more nucleotide differences comprises a protein capable of detecting mismatches between duplexed strands of nucleic acid.

74. The method of claim 69 wherein the physical separation by size of step (b) is accomplished using electrophoresis or density gradient centrifugation.

75. A method for accessing a sub-portion of a nucleic acid population, such method comprising:

5 a) mixing one or more oligonucleotide primers with a sample of said nucleic acid population under conditions which permit hybridization of one or more primers to said sample, each primer comprising a 3' terminal sequence which hybridizes to an anchor sequence present in said nucleic acid sample; and

b) adding deoxynucleotides and a template-dependent DNA polymerizing activity  
10 under conditions which permit extension of said one or more oligonucleotide primers, such that the population of extended primers comprises a sub-portion of nucleic acid molecules in said sample.

76. The method of claim 75 wherein said primer comprises an additional 3'-terminal extension immediately adjacent to said sequence which hybridizes to an anchor sequence.

15 77. The method of claim 76 wherein said additional 3' terminal extension is a mononucleotide selected from the group consisting of G, A, T and C.

78. The method of claim 76 wherein said additional 3' terminal extension is a dinucleotide selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

79. The method of claim 76 wherein said additional 3' terminal extension is a trinucleotide  
5 selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

10 80. The method of claim 76 wherein said additional 3' terminal extension is selected from the group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

81. The method of any one of claims 75-80 wherein the anchor sequence is the recognition  
sequence for a sequence-specific DNA binding activity selected from the group consisting of:  
15 transcription factors or DNA binding domains thereof; proteins with zinc finger DNA binding domains; restriction endonuclease DNA sequence recognition domains; sequence-specific antibodies; nucleic acid molecules; oligonucleotides complementary to an adapter ligated to a population of DNA molecules; aptamers; peptide nucleic acid molecules;

peptides; and affinity resins which recognize DNA having a particular G+C content or methylation status.

82. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to between about  
5 500 and 5000 nucleotides in length.

83. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 500 nucleotides in length.

84. The method of any one of claims 75-81 wherein an amount of chain-terminating  
10 nucleotide analogs is added sufficient to limit the average extension product to approximately 750 nucleotides in length.

85. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1000 nucleotides in length.

15 86. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1500 nucleotides in length.

87. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 2000 nucleotides in length.

88. The method of any one of claims 75-81 wherein an amount of chain-terminating  
5 nucleotide analogs is added sufficient to limit the average extension product to approximately 3000 nucleotides in length.

89. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 4000 nucleotides in length.

10 90. The method of any one of claims 75-81 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 5000 nucleotides in length.

91. The method of any one of claims 75-90 wherein said anchor sequence is a restriction endonuclease recognition sequence.

92. The method of claim 91 wherein said restriction endonuclease recognition sequence occurs infrequently in the genome of the organism from which the nucleic acid sample is obtained.

93. The method of claim 92 wherein said restriction endonuclease recognition sequence is  
5 selected from the group consisting of : AscI, BssHIII, EagI, NheI, NotI, PacI, PmeI, RsrII, SalI, SbfI, SfiI, SgrAI, SpeI, SrfI, and SwaI restriction endonuclease recognition sequences.

94. The method of any one of claims 75-93 wherein one or more of the oligonucleotides or deoxynucleotides is detectably labeled.

95. The method of claim 94 wherein the label is selected from the group consisting of:  
10 fluorescent moieties; radioactive moieties; biotin; and digoxigenin.

96. The method of any one of claims 75-95 wherein the oligonucleotide primer or primers is attached to a solid support or is labeled with a moiety allowing attachment to a solid support.

97. A method of identifying a nucleic acid sequence polymorphism comprising any one  
15 of the methods of claims 75-96 with the additional step of identifying a nucleic acid sequence polymorphism in a population of individuals.

98. A method of genotyping an individual with respect to a nucleic acid sequence polymorphism comprising any one of the methods of claims 75-96 with the additional step of identifying a nucleic acid sequence polymorphism in an individual.

99. A method for accessing a sub-population of a genome, such method comprising:

5 a) cleaving a nucleic acid sample with a first restriction endonuclease wherein the recognition sequence of said first restriction endonuclease occurs infrequently in the genome;

b) ligating an adapter molecule to the cleaved ends generated in step (a), said adapter having an overhang complementary to that generated by said first restriction endonuclease, and ligation of said adapter further regenerating all or part of the recognition sequence of said  
10 first restriction endonuclease;

c) mixing an oligonucleotide primer complementary to said adapter molecule, wherein the 3' terminus of said oligonucleotide primer is complementary to the regenerated recognition sequence of said first restriction endonuclease, under conditions which permit hybridization of said oligonucleotide primer to said adapter; and

15 d) adding deoxynucleotides and a template-dependent DNA polymerizing activity under conditions which permit extension of said oligonucleotide primer, the resulting population of primer extension products comprising a sub-portion of the molecules in said nucleic acid sample.

100. A method for accessing a sub-population of a genome, such method comprising:

a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments;

b) mixing one or more primers capable of annealing to nucleic acid fragment ends generated by said one or more cleavage agents and capable of initiating the replication of the  
5 nucleic acid regions comprising said fragment ends under conditions that permit said annealing;

c) incubating with a polymerizing activity under conditions that permit extension of said one or more primers, the resulting population of primer extension products comprising a sub-portion of the nucleic acid sequences in said genome, wherein said sub-portion of the  
10 nucleic acid sequences comprises an incomplete extension product.

101. The method of claim 100 wherein said cleavage agents are sequence-specific cleavage agents.

102. The method of claim 100 wherein said cleavage agents are sequence-specific cleavage agents and said primers comprise sequences complementary to the recognition sequence of  
15 said sequence-specific cleavage agents.

103. The method of claim 102 wherein said primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.



104. The method of claim 103 wherein said 3' end sequences comprise terminal extensions immediately adjacent to the sequence that hybridizes to said recognition sequence.

105. The method of claim 104 wherein said extensions are mononucleotides selected from the group consisting of: A, C, G, and T.

5 106. The method of claim 104 wherein said extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

107 The method of claim 104 wherein said extensions are trinucleotides selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG;  
10 ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

108. The method of claim 104 wherein said extension is selected from the group  
15 consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

109. A method for accessing a sub-population of a genome, such method comprising:

a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments;

b) operatively linking an adapter molecule to the cleaved ends generated in step (a);

c) incubating with a polymerizing activity under conditions that permit nucleic acid synthesis from said adapter, the resulting population of extension products comprising a sub-portion of the nucleic acid sequences in said genome, wherein said sub-portion of the nucleic acid sequences comprises an incomplete extension product.

110. The method of claim 109 wherein said adapter molecule contains a transcriptional promoter.

111. The method of claim 109 wherein said adapter molecule contains a free end capable of being extended by a polymerizing activity.

112. The method of claim 109 wherein the adapter molecule is double stranded and contains a sequence capable of being nicked by a second cleavage agent to produce a free end capable of being extended by a polymerizing activity.

113. A method for accessing a sub-population of a genome, such method comprising:

a) cleaving a nucleic acid sample with one or more cleavage agents to produce nucleic acid fragments;

b) operatively linking an adapter molecule to the cleaved ends generated in step (a);

c) mixing a primer complementary to said adapter molecule with the linked molecules generated in step (b) under conditions that permit hybridization of said primer to said adapter; and

d) incubating with a polymerizing activity under conditions that permit nucleic acid synthesis from said adapter, the resulting population of primer extension products comprising a sub-portion of said genome, wherein said sub-portion of said genome comprises an incomplete extension product.

114. The method of claim 113 wherein said cleavage agents are sequence-specific cleavage agents.

115. The method of claim 113 wherein said cleavage agents are sequence-specific cleavage agents and said primers comprise sequences complementary to the recognition sequence of said sequence-specific cleavage agents.

116. The method of claim 115 wherein said primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.

117. The method of claim 116 wherein said 3' end sequences comprise terminal extensions immediately adjacent to the sequence that hybridizes to the recognition sequence.

118. The method of claim 117 wherein said extensions are mononucleotides selected from the group consisting of: A, C, G, and T.

119. The method of claim 117 wherein said extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC;  
5 and TT.

120. The method of claim 117 wherein said extensions are trinucleotides selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.  
10

121. The method of claim 117 where in said extensions are selected from the group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides, and octanucleotides.

122. A method for accessing a sub-population of a genome, such method comprising:  
a) cleaving a nucleic acid sample with a cleavage agent;  
b) operatively linking an adapter molecule to the cleaved ends generated in step (a),  
said adapter having an end compatible with that generated by said cleavage agent;  
15

c) mixing a primer complementary to said adapter molecule, wherein the 3' terminus of said primer is complementary to the recognition sequence of said cleavage agent, under conditions that permit hybridization of said primer to said adapter; and

d) adding deoxynucleotides and a template-dependent polymerizing activity under  
5 conditions that permit extension of said oligonucleotide primer, the resulting population of primer extension products comprising a sub-portion of said genome.

123. The method of claim 122 wherein said cleavage agents are sequence-specific cleavage agents.

124. The method of claim 122 wherein said cleavage agents are sequence-specific cleavage  
10 agents and said primers comprise sequences complementary to the recognition sequence of said sequence-specific cleavage agents.

125. The method of claim 124 wherein said primers additionally comprise 3' end sequences capable of hybridizing to only a subset of the molecules in the nucleic acid sample.

126. The method of claim 125 wherein said 3' end sequences comprise terminal extensions  
15 immediately adjacent to the sequence that hybridizes to the recognition sequence

127. The method of claim 126 wherein said extensions are mononucleotides selected from the group consisting of: A, C, G, and T.

128. The method of claim 126 wherein said extensions are dinucleotides selected from the group consisting of: AA; AG; AC; AT; CA; CG; CC; CT; GA; GG; GC; GT; TA; TG; TC; and TT.

129. The method of claim 126 wherein said extensions are trinucleotides selected from the group consisting of: AAA; AAC; AAG; AAT; AGA; AGC; AGG; AGT; ACA; ACC; ACG; ACT; ATA; ATC; ATG; ATT; CAA; CAC; CAG; CAT; CCA; CCC; CCG; CCT; CGA; CGC; CGG; CGT; CTA; CTC; CTG; CTT; GAA; GAC; GAG; GAT; GCA; GCC; GCG; GCT; GGA; GGC; GGG; GGT; GTA; GTC; GTG; GTT; TAA; TAC; TAG; TAT; TCA; TCC; TCG; TCT; TGA; TGC; TGG; TGT; TTA; TTC; TTG; and TTT.

130. The method of claim 126 where in said extensions are selected from the group consisting of: tetranucleotides, pentanucleotides, hexanucleotides, septanucleotides and octanucleotides.

131. The method of any one of claims 99-130 wherein an amount of chain-terminating deoxynucleotide analogs is added sufficient to limit the length of the average extension product to between about 500 and 5000 nucleotides.

132. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 500 nucleotides in length.

133. The method of any one of claims 99-130 wherein an amount of chain-terminating  
5 nucleotide analogs is added sufficient to limit the average extension product to approximately 750 nucleotides in length.

134. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1000 nucleotides in length.

10 135. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 1500 nucleotides in length.

136. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately  
15 2000 nucleotides in length.

137. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 3000 nucleotides in length.

138. The method of any one of claims 99-130 wherein an amount of chain-terminating  
5 nucleotide analogs is added sufficient to limit the average extension product to approximately 4000 nucleotides in length.

139. The method of any one of claims 99-130 wherein an amount of chain-terminating nucleotide analogs is added sufficient to limit the average extension product to approximately 5000 nucleotides in length.

10 140. The method of any one of claims 99-130 wherein said oligonucleotide primer or one or more of said deoxynucleotides is detectably labeled.

141. The method of claim 140 wherein the label is selected from the group consisting of: fluorescent moieties; radioactive moieties; biotin; and digoxigenin.

142. The method of any one of claims 99-141 wherein said oligonucleotide primer is  
15 attached to a solid support.





**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS OF ENRICHING FOR AND IDENTIFYING POLYMORPHISMS**, the specification of which is attached hereto unless the following space is checked:

  X   is attached hereto.  
       was filed on \_\_\_\_\_ as United States Patent Application Serial Number or PCT International Application Number \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s): N/A

<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>	<u>Priority Not Claimed</u>
1.			<input type="checkbox"/>
2.			<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

<u>Application Number</u>	<u>Filing Date</u>
1.	
2.	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>Application Number</u>	<u>Filing Date</u>	<u>Status—patented, pending, abandoned</u>
1.		
2.		

I hereby appoint the following attorneys and agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<u>Kathleen Madden Williams</u>	Reg. No. 34,380	Ernest V. Linek	Reg. No. 29,822
Donald W. Banner	Reg. No. 17,037	Dale A. Malone	Reg. No. 32,155
Sheldon W. Witcoff	Reg. No. 17,399	Peter D. McDermott	Reg. No. 29,411
Robert F. Altherr	Reg. No. 31,810	Christopher L. McKee	Reg. No. 32,384
Mark T. Banner	Reg. No. 29,888	Edward F. McKie, Jr.	Reg. No. 17,335
Pamela I. Banner	Reg. No. 33,644	Nina L. Medlock	Reg. No. 29,673
William W. Beckett	Reg. No. 18,262	Timothy C. Meece	Reg. No. 38,553
James V. Callahan	Reg. No. 20,095	Frederic M. Meeker	Reg. No. 35,282
Alan I. Cantor	Reg. No. 28,163	Jon O. Nelson	Reg. No. 24,566
Gregory J. Cohan	Reg. No. 40,959	James A. Niegowski	Reg. No. 28,331
Marc S. Cooperman	Reg. No. 34,143	Thomas L. Peterson	Reg. No. 30,969
Laura J. Demoor	Reg. No. 39,654	Charles F. Pigott	Reg. No. 19,408
W. Dennis Drehkoff	Reg. No. 27,193	Joseph M. Potenza	Reg. No. 28,175
Gary D. Fedorochko	Reg. No. 35,509	Thomas K. Pratt	Reg. No. 37,210
Daniel E. Fisher	Reg. No. 32,133	Christopher J. Renk	Reg. No. 33,761
William J. Fisher	Reg. No. 34,162	Robert H. Resis	Reg. No. 31,168
Christopher R. Glembocki	Reg. No. 38,800	Steven P. Schad	Reg. No. 32,550
Brian E. Hanlon	Reg. No. 40,449	Michael H. Shanahan	Reg. No. 24,438
Patricia E. Hong	Reg. No. 34,373	Charles W. Shifley	Reg. No. 28,042
Dale H. Hoscheit	Reg. No. 19,090	Joseph M. Skerpon	Reg. No. 29,864
John P. Iwanicki	Reg. No. 34,628	J. Pieter Van Es	Reg. No. 37,746
Thomas H. Jackson	Reg. No. 29,808	Franklin D. Wolffe	Reg. No. 19,724
Sarah A. Kagan	Reg. No. 32,141	Susan A. Wolffe	Reg. No. 33,568
Robert S. Katz	Reg. No. 36,402	Bradley C. Wright	Reg. No. 38,061

as my Attorneys and as my Registered Patent Agents.

Address all telephone calls to Kathleen Madden Williams at (617) 227-7111.

Address all correspondence to Kathleen Madden Williams, BANNER & WITCOFF, LTD., 28 State Street, 28th Floor, Boston, MA 02109.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor (given name, family name):

**Joseph A. Sorge**

Inventor's signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Residence: 5320 Pine Meadow Road, Wilson, WY 83014  
Citizenship: United States of America  
Post Office Address: 5320 Pine Meadow Road, Wilson, WY 83014

Full name of second joint inventor, if any (given name, family name):

**Ronald W. Davis**

Inventor's signature: \_\_\_\_\_ Date: \_\_\_\_\_


Residence: Stanford Genome Center, 855 California Avenue, Palo Alto, California USA 94304

Citizenship: United States of America

Post Office Address: \_\_\_\_\_

66E290" 538E60

United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) 43 of Specification were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Scanned copy is best available.